{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:59:56Z","timestamp":1791388796597,"version":"4.3.3"},"reference-count":496,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0644","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:12:46Z","timestamp":1741367566000},"page":"545-635","source":"Crossref","is-referenced-by-count":37,"title":["The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-0706","authenticated-orcid":false,"given":"Iwao","family":"Sugitani","sequence":"first","affiliation":[{"name":"Department of Endocrine Surgery, Nippon Medical School, Tokyo 113-8603, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-6116","authenticated-orcid":false,"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe 650-0017, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2069-4658","authenticated-orcid":false,"given":"Yasuhiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4361-1827","authenticated-orcid":false,"given":"Naoyoshi","family":"Onoda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1073-0878","authenticated-orcid":false,"given":"Tomo","family":"Hiromasa","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8723-1906","authenticated-orcid":false,"given":"Kiyomi","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, Tokyo Women\u2019s Medical University, Tokyo 162-8666, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-4872","authenticated-orcid":false,"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Kanazawa University, Kanazawa 920-8641, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2268-0302","authenticated-orcid":false,"given":"Tetsuo","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Yamanashi, Yamanashi 409-3898, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6768-4107","authenticated-orcid":false,"given":"Sueyoshi","family":"Moritani","sequence":"additional","affiliation":[{"name":"Center for Head and Neck Thyroid Surgery, Oumi Medical Center, Shiga 525-8585, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-9871","authenticated-orcid":false,"given":"Kiminori","family":"Sugino","sequence":"additional","affiliation":[{"name":"Surgical Branch, Ito Hospital, Tokyo 150-8308, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-0353","authenticated-orcid":false,"given":"Hisato","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, University of Tsukuba, Tsukuba 305-8576, Japan"},{"name":"the Task Force of the Japan Association of Endocrine Surgery on the Guidelines for Thyroid Tumors"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","unstructured":"1 Committee MMD (2021) Minds Manual for Guideline Development 2020 ver. 3.0. https:\/\/minds.jcqhc.or.jp\/methods\/cpg-development\/minds-manual\/ accessed on Feb 13, 2024 (In Japanese)."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973\u20132002. JAMA 295: 2164\u20132167.","DOI":"10.1001\/jama.295.18.2164"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Lin JS, Bowles EJA, Williams SB, Morrison CC (2017) Screening for thyroid cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 317: 1888\u20131903.","DOI":"10.1001\/jama.2017.0562"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Horiguchi K, Yoshida Y, Iwaku K, Emoto N, Kasahara T, et al. (2021) Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults. Endocr J 68: 763\u2013780.","DOI":"10.1507\/endocrj.EJ20-0692"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Furuya-Kanamori L, Bell KJL, Clark J, Glasziou P, Doi SAR (2016) Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol 34: 3672\u20133679.","DOI":"10.1200\/JCO.2016.67.7419"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Morris LG, Sikora AG, Tosteson TD, Davies L (2013) The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23: 885\u2013891.","DOI":"10.1089\/thy.2013.0045"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Zevallos JP, Hartman CM, Kramer JR, Sturgis EM, Chiao EY (2015) Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: a study of the Veterans Affairs health care system. Cancer 121: 741\u2013746.","DOI":"10.1002\/cncr.29122"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8 Ahn HS, Kim HJ, Kim KH, Lee YS, Han SJ, et al. (2016) Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid 26: 1535\u20131540.","DOI":"10.1089\/thy.2016.0075"},{"key":"9","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1186\/s12885-020-07597-4","volume":"20","author":"HY Kang","year":"2020","unstructured":"9 Kang HY, Kim I, Kim YY, Bahk J, Khang YH (2020) Income differences in screening, incidence, postoperative complications, and mortality of thyroid cancer in South Korea: a national population-based time trend study. BMC Cancer 20: 1096.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Park S, Oh CM, Cho H, Lee JY, Jung KW, et al. (2016) Association between screening and the thyroid cancer \u201cepidemic\u201d in South Korea: evidence from a nationwide study. BMJ 355: i5745.","DOI":"10.1136\/bmj.i5745"},{"key":"11","unstructured":"11 Takebe K, Ito M, Yamamoto Y, Hagino T, Takeuchi Y (1994) Mass screening for thyroid cancer with ultrasonography. KARKINOS 7: 309\u2013317 (In Japanese)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Ahn HS, Kim HJ, Welch HG (2014) Korea\u2019s thyroid-cancer \u201cepidemic\u201d\u2014screening and overdiagnosis. N Engl J Med 371: 1765\u20131767.","DOI":"10.1056\/NEJMp1409841"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Jun JK, Hwang SY, Hong S, Suh M, Choi KS, et al. (2020) Association of screening by thyroid US with mortality in thyroid cancer: a case-control study using data from two national surveys. Thyroid 30: 396\u2013400.","DOI":"10.1089\/thy.2019.0460"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Liu Y, Lai F, Long J, Peng S, Wang H, et al. (2021) Screening and the epidemic of thyroid cancer in China: an analysis of national representative inpatient and commercial insurance databases. Int J Cancer 148: 1106\u20131114.","DOI":"10.1002\/ijc.33298"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Yang N, Yang H, Guo JJ, Hu M, Li S (2021) Cost-effectiveness analysis of ultrasound screening for thyroid cancer in asymptomatic adults. Front Public Health 9: 729684.","DOI":"10.3389\/fpubh.2021.729684"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Abu-Yousef MM, Larson JH, Kuehn DM, Wu AS, Laroia AT (2011) Safety of ultrasound-guided fine needle aspiration biopsy of neck lesions in patients taking antithrombotic\/anticoagulant medications. Ultrasound Q 27: 157\u2013159.","DOI":"10.1097\/RUQ.0b013e31822b5681"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, et al. (2005) Needle tract implantation of PTC after fine-needle aspiration biopsy. World J Surg 29: 1544\u20131549.","DOI":"10.1007\/s00268-005-0086-x"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18 Oda H, Miyauchi A, Ito Y, Yoshioka K, Nakayama A, et al. (2016) Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance <i>versus<\/i> immediate surgery. Thyroid 26: 150\u2013155.","DOI":"10.1089\/thy.2015.0313"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19 Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, et al. (2017) Screening for thyroid cancer: US preventive services task force recommendation statement. JAMA 317: 1882\u20131887.","DOI":"10.1001\/jama.2017.4011"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Messuti I, Corvisieri S, Bardesono F, Rapa I, Giorcelli J, et al. (2014) Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features. Eur J Endocrinol 170: 659\u2013666.","DOI":"10.1530\/EJE-13-0903"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Chen AC, Livhits MJ, Du L, Wu JX, Kuo EJ, et al. (2018) Recent pregnancy is not associated with high-risk pathological features of well-differentiated thyroid cancer. Thyroid 28: 68\u201371.","DOI":"10.1089\/thy.2017.0496"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Ito Y, Miyauchi A, Kudo T, Ota H, Yoshioka K, et al. (2016) Effects of pregnancy on papillary microcarcinomas of the thyroid re-evaluated in the entire patient series at Kuma hospital. Thyroid 26: 156\u2013160.","DOI":"10.1089\/thy.2015.0393"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Oh HS, Kim WG, Park S, Kim M, Kwon H, et al. (2017) Serial neck ultrasonographic evaluation of changes in PTC during pregnancy. Thyroid 27: 773\u2013777.","DOI":"10.1089\/thy.2016.0618"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Xi C, Zhang Q, Song HJ, Shen CT, Zhang GQ, et al. (2021) Pregnancy does not affect the prognoses of differentiated thyroid cancer patients with lung metastases. J Clin Endocrinol Metab 106: e3185\u2013e3197.","DOI":"10.1210\/clinem\/dgab111"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25 Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, et al. (2017) 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27: 315\u2013389.","DOI":"10.1089\/thy.2016.0457"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Uruno T, Shibuya H, Kitagawa W, Nagahama M, Sugino K, et al. (2014) Optimal timing of surgery for differentiated thyroid cancer in pregnant women. World J Surg 38: 704\u2013708.","DOI":"10.1007\/s00268-013-2334-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Ito Y, Onoda N, Okamoto T (2020) The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: core questions and recommendations for treatments of thyroid cancer. Endocr J 67: 669\u2013717.","DOI":"10.1507\/endocrj.EJ20-0025"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Ito Y, Miyauchi A, Oda H, Masuoka H, Higashiyama T, et al. (2019) Appropriateness of the revised Japanese guidelines\u2019 risk classification for the prognosis of PTC: a retrospective analysis of 5,845 papilla y thyroid carcinoma patients. Endocr J 66: 127\u2013134.","DOI":"10.1507\/endocrj.EJ17-0061"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Yamazaki H, Masudo K, Rino Y (2023) Migration of risk classification between the JAES <i>versus<\/i> ATA guidelines for PTC. World J Surg 47: 1729\u20131737.","DOI":"10.1007\/s00268-023-06976-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Ito Y, Miyauchi A, Yamamoto M, Masuoka H, Higashiyama T, et al. (2020) Subset analysis of the Japanese risk classification guidelines for PTC. Endocr J 67: 275\u2013282.","DOI":"10.1507\/endocrj.EJ19-0387"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Ito Y, Yoshida H, Maruo R, Morita S, Takano T, et al. (2009) Mutation in PTC in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56: 89\u201397.","DOI":"10.1507\/endocrj.K08E-208"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Matsuse M, Yabuta T, Saenko V, Hirokawa M, Nishihara E, et al. (2017) Promoter mutations and Ki-67 labeling index as a prognostic marker of PTCs: combination of two independent factors. Sci Rep 7: 41752.","DOI":"10.1038\/srep41752"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Xing M, Liu R, Liu X, Murugan AK, Zhu G, et al. (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32: 2718\u20132726.","DOI":"10.1200\/JCO.2014.55.5094"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Ebina A, Togashi Y, Baba S, Sato Y, Sakata S, et al. (2020) TERT promoter mutation and extent of thyroidectomy in patients with 1\u20134 cm intrathyroidal papillary carcinoma. Cancers (Basel) 12: 2115.","DOI":"10.3390\/cancers12082115"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Vuong HG, Altibi AMA, Duong UNP, Hassell L (2017) Prognostic implication of BRAF and TERT promoter mutation combination in PTC-A meta-analysis. Clin Endocrinol (Oxf) 87: 411\u2013417.","DOI":"10.1111\/cen.13413"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Yin DT, Yu K, Lu RQ, Li XH, Xu JH, et al. (2016) Clinicopathological significance of TERT promoter mutation in PTCs: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 85: 299\u2013305.","DOI":"10.1111\/cen.13017"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37 Meng ZW, Matsuse M, Saenko V, Yamashita S, Ren P, et al. (2019) TERT promoter mutation in primary PTC lesions predicts absent or lower 131i uptake in metastases. IUBMB Life 71: 1030\u20131040.","DOI":"10.1002\/iub.2056"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, et al. (2019) TERT mRNA expression as a novel prognostic marker in PTCs. Thyroid 29: 1105\u20131114.","DOI":"10.1089\/thy.2018.0695"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39 Yabuta T, Matsuse M, Hirokawa M, Yamashita S, Mitsutake N, et al. (2017) TERT promoter mutations were not found in papillary thyroid microcarcinomas that showed disease progression on active surveillance. Thyroid 27: 1206\u20131207.","DOI":"10.1089\/thy.2016.0645"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Lee J, Ha EJ, Roh J, Kim HK (2021) Presence of TERT \u00b1 BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. Surgery 170: 743\u2013747.","DOI":"10.1016\/j.surg.2021.03.056"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, et al. (2015) TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid 25: 1013\u20131019.","DOI":"10.1089\/thy.2015.0101"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42 Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, et al. (2021) Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery Task Force on management for papillary thyroid microcarcinoma. Thyroid 31: 183\u2013192.","DOI":"10.1089\/thy.2020.0330"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Ito Y, Miyauchi A, Fujishima M, Noda T, Sano T, et al. (2023) Thyroid-stimulating hormone, age, and tumor size are risk factors for progression during active surveillance of low-risk papillary thyroid microcarcinoma in adults. World J Surg 47: 392\u2013401.","DOI":"10.1007\/s00268-022-06770-z"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Lee EK, Moon JH, Hwangbo Y, Ryu CH, Cho SW, et al. (2022) Progression of low-risk papillary thyroid microcarcinoma during active surveillance: interim analysis of a multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma in Korea. Thyroid 32: 1328\u20131336.","DOI":"10.1089\/thy.2021.0614"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Nagaoka R, Ebina A, Toda K, Jikuzono T, Saitou M, et al. (2021) Multifocality and progression of papillary thyroid microcarcinoma during active surveillance. World J Surg 45: 2769\u20132776.","DOI":"10.1007\/s00268-021-06185-2"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46 Tuttle RM, Fagin J, Minkowitz G, Wong R, Roman B, et al. (2022) Active surveillance of papillary thyroid cancer: frequency and time course of the six most common tumor volume kinetic patterns. Thyroid 32: 1337\u20131345.","DOI":"10.1089\/thy.2022.0325"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Oh HS, Ha J, Kim HI, Kim TH, Kim WG, et al. (2018) Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea. Thyroid 28: 1587\u20131594.","DOI":"10.1089\/thy.2018.0263"},{"key":"48","doi-asserted-by":"publisher","unstructured":"48 Sanabria A (2020) Experience with active surveillance of thyroid low-risk carcinoma in a developing country. Thyroid 30: 985\u2013991.","DOI":"10.1089\/thy.2019.0522"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, et al. (2020) Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single italian center. J Clin Endocrinol Metab 105: E172\u2013E180.","DOI":"10.1210\/clinem\/dgz113"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Rosario PW, Mourao GF, Calsolari MR (2019) Active surveillance in adults with low-risk papillary thyroid microcarcinomas: a prospective study. Horm Metab Res 51: 703\u2013708.","DOI":"10.1055\/a-1015-6684"},{"key":"51","doi-asserted-by":"publisher","unstructured":"51 Miyauchi A, Ito Y, Fujishima M, Miya A, Onoda N, et al. (2023) Long-term outcomes of active surveillance and immediate surgery for adult patients with low-risk papillary thyroid microcarcinoma: 30-year experience. Thyroid 33: 817\u2013825.","DOI":"10.1089\/thy.2023.0076"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52 Miyauchi A, Kudo T, Ito Y, Oda H, Sasai H, et al. (2018) Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery 163: 48\u201352.","DOI":"10.1016\/j.surg.2017.03.028"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Ito Y, Miyauchi A, Kudo T, Higashiyama T, Masuoka H, et al. (2019) Kinetic analysis of growth activity in enlarging papillary thyroid microcarcinomas. Thyroid 29: 1765\u20131773.","DOI":"10.1089\/thy.2019.0396"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, et al. (2017) Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg 143: 1015\u20131020.","DOI":"10.1001\/jamaoto.2017.1442"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Chou R, Dana T, Haymart M, Leung AM, Tufano RP, et al. (2022) Active surveillance <i>versus<\/i> thyroid surgery for differentiated thyroid cancer: a systematic review. Thyroid 32: 351\u2013367.","DOI":"10.1089\/thy.2021.0539"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Fujishima M, Miyauchi A, Ito Y, Kudo T, Noda T, et al. (2023) Active surveillance is an excellent management technique for identifying patients with progressive low-risk papillary thyroid microcarcinoma requiring surgical treatment. Endocr J 70: 411\u2013418.","DOI":"10.1507\/endocrj.EJ22-0559"},{"key":"57","doi-asserted-by":"publisher","unstructured":"57 Sasaki T, Miyauchi A, Fujishima M, Ito Y, Kudo T, et al. (2023) Comparison of postoperative unfavorable events in patients with low-risk PTC: immediate surgery <i>versus<\/i> conversion surgery following active surveillance. Thyroid 33: 186\u2013191.","DOI":"10.1089\/thy.2022.0444"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Oda H, Miyauchi A, Ito Y, Sasai H, Masuoka H, et al. (2017) Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. Endocr J 64: 59\u201364.","DOI":"10.1507\/endocrj.EJ16-0381"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Jeon MJ, Lee YM, Sung TY, Han M, Shin YW, et al. (2019) Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy: a cross-sectional study. Thyroid 29: 956\u2013962.","DOI":"10.1089\/thy.2018.0711"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Yoshida Y, Horiuchi K, Okamoto T (2020) Patients\u2019 view on the management of papillary thyroid microcarcinoma: active surveillance or surgery. Thyroid 30: 681\u2013687.","DOI":"10.1089\/thy.2019.0420"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Nakamura T, Miyauchi A, Ito Y, Ito M, Kudo T, et al. (2020) Quality of life in patients with low-risk papillary thyroid microcarcinoma: active surveillance <i>versus<\/i> immediate surgery. Endocr Pract 26: 1451\u20131457.","DOI":"10.4158\/EP-2020-0201"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Kazusaka H, Sugitani I, Toda K, Sen M, Saito M, et al. (2023) Patient-reported outcomes in patients with low-risk PTC: cross-sectional study to compare active surveillance and immediate surgery. World J Surg 47: 1190\u20131198.","DOI":"10.1007\/s00268-022-06786-5"},{"key":"63","doi-asserted-by":"publisher","unstructured":"63 Kong SH, Ryu J, Kim MJ, Cho SW, Song YS, et al. (2019) Longitudinal assessment of quality of life according to treatment options in low-risk papillary thyroid microcarcinoma patients: active surveillance or immediate surgery (interim analysis of MAeSTro). Thyroid 29: 1089\u20131096.","DOI":"10.1089\/thy.2018.0624"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Moon JH, Ryu CH, Cho SW, Choi JY, Chung EJ, et al. (2021) Effect of initial treatment choice on 2-year quality of life in patients with low-risk papillary thyroid microcarcinoma. J Clin Endocrinol Metab 106: 724\u2013735.","DOI":"10.1210\/clinem\/dgaa889"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Ito Y, Masuoka H, Fukushima M, Inoue H, Kihara M, et al. (2010) Excellent prognosis of patients with solitary T1N0M0 PTC who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy. World J Surg 34: 1285\u20131290.","DOI":"10.1007\/s00268-009-0356-0"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Sugitani I, Fujimoto Y (2010) Management of low-risk PTC: unique conventional policy in Japan and our efforts to improve the level of evidence. Surg Today 40: 199\u2013215.","DOI":"10.1007\/s00595-009-4034-5"},{"key":"67","doi-asserted-by":"publisher","unstructured":"67 Ebina A, Sugitani I, Fujimoto Y, Yamada K (2014) Risk-adapted management of PTC according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients? Surgery 156: 1579\u20131588; discussion 1588\u20131589.","DOI":"10.1016\/j.surg.2014.08.060"},{"key":"68","doi-asserted-by":"publisher","unstructured":"68 Kim SK, Park I, Woo JW, Lee JH, Choe JH, et al. (2017) Total thyroidectomy <i>versus<\/i> lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8,676 patients at a single institution. Surgery 161: 485\u2013492.","DOI":"10.1016\/j.surg.2016.07.037"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Kwon H, Jeon MJ, Kim WG, Park S, Kim M, et al. (2017) A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. Eur J Endocrinol 176: 371\u2013378.","DOI":"10.1530\/EJE-16-0845"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Jeon YW, Gwak HG, Lim ST, Schneider J, Suh YJ (2019) Long-term prognosis of unilateral and multifocal papillary thyroid microcarcinoma after unilateral lobectomy <i>versus<\/i> total thyroidectomy. Ann Surg Oncol 26: 2952\u20132958.","DOI":"10.1245\/s10434-019-07482-w"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Zhang C, Li YS, Li JY, Chen X (2020) Total thyroidectomy <i>versus<\/i> lobectomy for papillary thyroid cancer A systematic review and meta-analysis. Medicine (Baltimore) 99: e19073.","DOI":"10.1097\/MD.0000000000019073"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Bongers PJ, Greenberg CA, Hsiao R, Vermeer M, Vriens MR, et al. (2020) Differences in long-term quality of life between hemithyroidectomy and total thyroidectomy in patients treated for low-risk differentiated thyroid carcinoma. Surgery 167: 94\u2013101.","DOI":"10.1016\/j.surg.2019.04.060"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Yang XT, Yang Q, Tang Y, Ma J, Ye HM (2021) Impact of the extent of thyroidectomy on quality of life in differentiated thyroid cancer survivors: a propensity score matched analysis. Cancer Manag Res 13: 6953\u20136967.","DOI":"10.2147\/CMAR.S321988"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Nickel B, Tan T, Cvejic E, Baade P, McLeod DSA, et al. (2019) Health-related quality of life after diagnosis and treatment of differentiated thyroid cancer and association with type of surgical treatment. JAMA Otolaryngol Head Neck Surg 145: 231\u2013238.","DOI":"10.1001\/jamaoto.2018.3870"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Chen W, Li J, Peng S, Hong S, Xu H, et al. (2022) Association of total thyroidectomy or thyroid lobectomy with the quality of life in patients with differentiated thyroid cancer with low to intermediate risk of recurrence. JAMA Surg 157: 200\u2013209.","DOI":"10.1001\/jamasurg.2021.6442"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Maki Y, Horiuchi K, Okamoto T (2022) Fatigue and quality of life among thyroid cancer survivors without persistent or recurrent disease. Endocr Connect 11: e210506.","DOI":"10.1530\/EC-21-0506"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Ito M, Miyauchi A, Morita S, Kudo T, Nishihara E, et al. (2012) TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol 167: 373\u2013378.","DOI":"10.1530\/EJE-11-1029"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, et al. (2007) Risk factors for recurrence to the lymph node in PTC patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg 31: 2085\u20132091.","DOI":"10.1007\/s00268-007-9224-y"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Ducoudray R, Tresallet C, Godiris-Petit G, Tissier F, Leenhardt L, et al. (2013) Prophylactic lymph node dissection in PTC: is there a place for lateral neck dissection? World J Surg 37: 1584\u20131591.","DOI":"10.1007\/s00268-013-2020-y"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Sugitani I, Fujimoto Y, Yamada K, Yamamoto N (2008) Prospective outcomes of selective lymph node dissection for PTC based on preoperative US. World J Surg 32: 2494\u20132502.","DOI":"10.1007\/s00268-008-9711-9"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Ito Y, Tsushima Y, Masuoka H, Yabuta T, Fukushima M, et al. (2011) Significance of prophylactic modified radical neck dissection for patients with low-risk PTC measuring 1.1\u20133.0 cm: first report of a trial at Kuma Hospital. Surg Today 41: 1486\u20131491.","DOI":"10.1007\/s00595-010-4494-7"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Ito Y, Miyauchi A, Kudo T, Kihara M, Fukushima M, et al. (2017) The effectiveness of prophylactic modified neck dissection for reducing the development of lymph node recurrence of PTC. World J Surg 41: 2283\u20132289.","DOI":"10.1007\/s00268-017-4023-6"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Takamura Y, Miyauchi A, Tomoda C, Uruno T, Ito Y, et al. (2005) Stretching exercises to reduce symptoms of postoperative neck discomfort after thyroid surgery: prospective randomized study. World J Surg 29: 775\u2013779.","DOI":"10.1007\/s00268-005-7722-3"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, et al. (2014) Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 38: 68\u201379.","DOI":"10.1007\/s00268-013-2224-1"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 MacKinney EC, Kuchta KM, Winchester DJ, Khokar AM, Holoubek SA, et al. (2022) Overall survival is improved with total thyroidectomy and radiation for male patients and patients older than 55 with T2N0M0 Stage 1 classic papillary thyroid cancer. Surgery 171: 197\u2013202.","DOI":"10.1016\/j.surg.2021.08.025"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Sugitani I, Kazusaka H, Ebina A, Shimbashi W, Toda K, et al. (2023) Long-term outcomes after lobectomy for patients with high-risk PTC. World J Surg 47: 382\u2013391.","DOI":"10.1007\/s00268-022-06705-8"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Haigh PI, Urbach DR, Rotstein LE (2005) Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 12: 81\u201389.","DOI":"10.1007\/s10434-004-1165-1"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Adam MA, Pura J, Goffredo P, Dinan MA, Hyslop T, et al. (2015) Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J Clin Endocrinol Metab 100: 115\u2013121.","DOI":"10.1210\/jc.2014-3039"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Liu J, Zhang ZM, Huang H, Xu SY, Liu Y, et al. (2019) Total thyroidectomy <i>versus<\/i> lobectomy for intermediate-risk PTC: a single-institution matched-pair analysis. Oral Oncology 90: 17\u201322.","DOI":"10.1016\/j.oraloncology.2019.01.010"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD (2011) Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 33: 645\u2013649.","DOI":"10.1002\/hed.21504"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Wanebo H, Coburn M, Teates D, Cole B (1998) Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 227: 912\u2013918.","DOI":"10.1097\/00000658-199806000-00015"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Choi JB, Lee SG, Kim MJ, Kim TH, Ban EJ, et al. (2019) Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy. Head Neck 41: 56\u201363.","DOI":"10.1002\/hed.25356"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Xu S, Huang H, Wang X, Liu S, Xu Z, et al. (2021) Long-term outcomes of lobectomy for PTC with high-risk features. Br J Surg 108: 395\u2013402.","DOI":"10.1093\/bjs\/znaa129"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Qu N, Zhang L, Ji QH, Chen JY, Zhu YX, et al. (2015) Risk factors for central compartment lymph node metastasis in papillary thyroid microcarcinoma: a meta-analysis. World J Surg 39: 2459\u20132470.","DOI":"10.1007\/s00268-015-3108-3"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Hughes DT, Rosen JE, Evans DB, Grubbs E, Wang TS, et al. (2018) Prophylactic central compartment neck dissection in papillary thyroid cancer and effect on locoregional recurrence. Ann Surg Oncol 25: 2526\u20132534.","DOI":"10.1245\/s10434-018-6528-0"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Lang BHH, Ng SH, Lau LLH, Cowling BJ, Wong KP, et al. (2013) A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in PTC after total thyroidectomy. Thyroid 23: 1087\u20131098.","DOI":"10.1089\/thy.2012.0608"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Chen L, Wu YH, Lee CH, Chen HA, Loh EW, et al. (2018) Prophylactic central neck dissection for PTC with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis. World J Surg 42: 2846\u20132857.","DOI":"10.1007\/s00268-018-4547-4"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Liu H, Li Y, Mao Y (2019) Local lymph node recurrence after central neck dissection in papillary thyroid cancers: a meta analysis. Eur Ann Otorhinolaryngol Head Neck Dis 136: 481\u2013487.","DOI":"10.1016\/j.anorl.2018.07.010"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Qu H, Sun GR, Liu Y, He QS (2015) Clinical risk factors for central lymph node metastasis in PTC: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 83: 124\u2013132.","DOI":"10.1111\/cen.12583"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Zhao WJ, Luo H, Zhou YM, Dai WY, Zhu JQ (2017) Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for cN0 PTC: an updated meta-analysis. Eur J Surg Oncol 43: 1989\u20132000.","DOI":"10.1016\/j.ejso.2017.07.008"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Zhao WJ, You L, Hou XM, Chen SB, Ren XX, et al. (2017) The effect of prophylactic central neck dissection on locoregional recurrence in papillary thyroid cancer after total thyroidectomy: a systematic review and meta-analysis pCND for the locoregional recurrence of papillary thyroid cancer. Ann Surg Oncol 24: 2189\u20132198.","DOI":"10.1245\/s10434-016-5691-4"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 Ito Y, Miyauchi A, Masuoka H, Fukushima M, Kihara M, et al. (2018) Excellent prognosis of central lymph node recurrence-free survival for cN0M0 PTC patients who underwent routine prophylactic central node dissection. World J Surg 42: 2462\u20132468.","DOI":"10.1007\/s00268-018-4497-x"},{"key":"103","doi-asserted-by":"publisher","unstructured":"103 Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, et al. (2012) American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for PTC. Thyroid 22: 237\u2013244.","DOI":"10.1089\/thy.2011.0317"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104 Kim BY, Choi N, Kim SW, Jeong HS, Chung MK, et al. (2020) Randomized trial of prophylactic ipsilateral central lymph node dissection in patients with clinically node negative papillary thyroid microcarcinoma. Eur Arch Otorhinolaryngol 277: 569\u2013576.","DOI":"10.1007\/s00405-019-05702-3"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105 Lee DY, Oh KH, Cho JG, Kwon SY, Woo JS, et al. (2015) The benefits and risks of prophylactic central neck dissection for PTC: prospective cohort study. Int J Endocrinol 2015: 571480.","DOI":"10.1155\/2015\/571480"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, et al. (2015) Prophylactic central compartment lymph node dissection in PTC: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab 100: 1316\u20131324.","DOI":"10.1210\/jc.2014-3825"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107 Sippel RS, Robbins SE, Poehls JL, Pitt SC, Chen HR, et al. (2020) A randomized controlled clinical trial no clear benefit to prophylactic central neck dissection in patients with clinically node negative papillary thyroid cancer. Ann Surg 272: 496\u2013503.","DOI":"10.1097\/SLA.0000000000004345"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108 Ahn JH, Kwak JH, Yoon SG, Yi JW, Yu HW, et al. (2022) A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in PTC. Surgery 171: 182\u2013189.","DOI":"10.1016\/j.surg.2021.03.071"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109 Sanabria A, Betancourt-Ag\u00fcero C, S\u00e1nchez-Delgado JG, Garc\u00eda-Lozano C (2022) Prophylactic central neck lymph node dissection in low-risk thyroid carcinoma patients does not decrease the incidence of locoregional recurrence: a meta-analysis of randomized trials. Ann Surg 276: 66\u201373.","DOI":"10.1097\/SLA.0000000000005388"},{"key":"110","doi-asserted-by":"publisher","unstructured":"110 Alsubaie KM, Alsubaie HM, Alzahrani FR, Alessa MA, Abdulmonem SK, et al. (2022) Prophylactic central neck dissection for clinically node-negative PTC. Laryngoscope 132: 1320\u20131328.","DOI":"10.1002\/lary.29912"},{"key":"111","unstructured":"112 Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, et al. (2004) Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 45: 988\u2013994."},{"key":"112","doi-asserted-by":"crossref","unstructured":"113 Jeon S, Kwon SY, Ryu YJ, Kang SR, Yoo SW, et al. (2020) Combined role of lymph node ratio and serum thyroglobulin levels in predicting prognosis of PTC. Nucl Med Commun 41: 733\u2013739.","DOI":"10.1097\/MNM.0000000000001214"},{"key":"113","doi-asserted-by":"crossref","unstructured":"114 Haddady S, Pinjic E, Lee SL (2021) Prognostic value of serum thyroglobulin measured at 48 hours <i>versus<\/i> 72 hours after second dose of recombinant human thyrotropin in surveillance of well-differentiated thyroid cancer. Endocr Pract 27: 216\u2013222.","DOI":"10.1016\/j.eprac.2020.09.002"},{"key":"114","doi-asserted-by":"crossref","unstructured":"115 Jammah AA, Masood A, Akkielah LA, Alhaddad S, Alhaddad MA, et al. (2021) Utility of stimulated thyroglobulin in reclassifying low risk thyroid cancer patients\u2019 following thyroidectomy and radioactive iodine ablation: a 7-year prospective trial. Front Endocrinol (Lausanne) 11: 6033432.","DOI":"10.3389\/fendo.2020.603432"},{"key":"115","doi-asserted-by":"crossref","unstructured":"116 Zanella AB, Scheffel RS, Nava CF, Golbert L, Laurini de Souza Meyer E, et al. (2018) Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer. Thyroid 28: 1285\u20131292.","DOI":"10.1089\/thy.2018.0075"},{"key":"116","doi-asserted-by":"publisher","unstructured":"117 Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, et al. (2011) Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with PTC who underwent total thyroidectomy. Thyroid 21: 707\u2013716.","DOI":"10.1089\/thy.2010.0355"},{"key":"117","doi-asserted-by":"crossref","unstructured":"118 Tsushima Y, Miyauchi A, Ito Y, Kudo T, Masuoka H, et al. (2013) Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive PTC patients. Endocr J 60: 871\u2013876.","DOI":"10.1507\/endocrj.EJ12-0410"},{"key":"118","doi-asserted-by":"crossref","unstructured":"119 Chou R, Dana T, Brent GA, Goldner W, Haymart M, et al. (2022) Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: a systematic review. Thyroid 32: 613\u2013639.","DOI":"10.1089\/thy.2021.0666"},{"key":"119","doi-asserted-by":"crossref","unstructured":"120 Xu SY, Huang H, Zhang XH, Huang Y, Guan B, et al. (2021) Predictive value of serum thyroglobulin for structural recurrence following lobectomy for PTC. Thyroid 31: 1391\u20131399.","DOI":"10.1089\/thy.2021.0209"},{"key":"120","doi-asserted-by":"crossref","unstructured":"121 Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, GTE Study Group (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90: 6077\u20136084.","DOI":"10.1210\/jc.2005-0044"},{"key":"121","doi-asserted-by":"crossref","unstructured":"122 Ito Y, Onoda N, Kihara M, Miya A, Miyauchi A (2021) Prognostic significance of neutrophil-to-lymphocyte ratio in differentiated thyroid carcinoma having distant metastasis: a comparison with thyroglobulin-doubling rate and tumor volume-doubling rate. In Vivo 35: 1125\u20131132.","DOI":"10.21873\/invivo.12358"},{"key":"122","doi-asserted-by":"crossref","unstructured":"123 Ito Y, Onoda N, Kudo T, Masuoka H, Higashiyama T, et al. (2021) Sorafenib and lenvatinib treatment for metastasis\/recurrence of radioactive iodine-refractory differentiated thyroid carcinoma. In Vivo 35: 1057\u20131064.","DOI":"10.21873\/invivo.12350"},{"key":"123","doi-asserted-by":"crossref","unstructured":"124 Fukuda N, Toda K, Fujiwara YU, Wang X, Ohmoto A, et al. (2020) Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib. In Vivo 34: 2859\u20132864.","DOI":"10.21873\/invivo.12113"},{"key":"124","doi-asserted-by":"crossref","unstructured":"125 Sugitani I, Fujimoto Y (2010) Does postoperative thyrotropin suppression therapy truly decrease recurrence in PTC? A randomized controlled trial. J Clin Endocrinol Metab 95: 4576\u20134583.","DOI":"10.1210\/jc.2010-0161"},{"key":"125","doi-asserted-by":"crossref","unstructured":"126 Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, et al. (2007) Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 92: 2610\u20132615.","DOI":"10.1210\/jc.2006-2566"},{"key":"126","doi-asserted-by":"crossref","unstructured":"127 Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, et al. (2015) Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987\u20132012. J Clin Endocrinol Metab 100: 3270\u20133279.","DOI":"10.1210\/JC.2015-1346"},{"key":"127","doi-asserted-by":"crossref","unstructured":"128 Wang LY, Smith AW, Palmer FL, Tuttle RM, Mahrous A, et al. (2015) Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid 25: 300\u2013307.","DOI":"10.1089\/thy.2014.0287"},{"key":"128","doi-asserted-by":"crossref","unstructured":"129 Lee MC, Kim MJ, Choi HS, Cho SW, Lee GH, et al. (2019) Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid cancer. Endocrinol Metab (Seoul) 34: 150\u2013157.","DOI":"10.3803\/EnM.2019.34.2.150"},{"key":"129","unstructured":"130 Xiang YY, Xu YY, Bhandari A, Sindan N, Hirachan S, et al. (2021) Serum TSH levels are associated with postoperative recurrence and lymph node metastasis of PTC. Am J Transl Res 13: 6108\u20136116."},{"key":"130","doi-asserted-by":"crossref","unstructured":"131 Parker WA, Edafe O, Balasubramanian SP (2017) Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature. Pragmat Obs Res 8: 57\u201367.","DOI":"10.2147\/POR.S130510"},{"key":"131","doi-asserted-by":"crossref","unstructured":"132 Sugitani I, Fujimoto Y (2011) Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with PTC: a prospective controlled study. Surgery 150: 1250\u20131256.","DOI":"10.1016\/j.surg.2011.09.013"},{"key":"132","doi-asserted-by":"crossref","unstructured":"133 Ito M, Miyauchi A, Hisakado M, Yoshioka W, Ide A, et al. (2017) Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. Thyroid 27: 484\u2013490.","DOI":"10.1089\/thy.2016.0426"},{"key":"133","doi-asserted-by":"crossref","unstructured":"134 Klein Hesselink EN, Klein Hesselink MS, de Bock GH, Gansevoort RT, Bakker SJ, et al. (2013) Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 31: 4046\u20134053.","DOI":"10.1200\/JCO.2013.49.1043"},{"key":"134","doi-asserted-by":"crossref","unstructured":"135 Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, et al. (2013) Diagnostic accuracy of fine needle aspiration biopsy cytology and US in patients with thyroid nodules diagnosed as benign or indeterminate before thyroidectomy. Endocr J 60: 375\u2013382.","DOI":"10.1507\/endocrj.EJ12-0338"},{"key":"135","doi-asserted-by":"crossref","unstructured":"136 Kihara M, Miyauchi A, Hirokawa M, Masuoka H, Higashiyama T, et al. (2021) Long-term outcomes of cytologically benign thyroid tumors: a retrospective analysis of 3,102 patients at a single institution. Endocr J 68: 1373\u20131381.","DOI":"10.1507\/endocrj.EJ21-0252"},{"key":"136","doi-asserted-by":"crossref","unstructured":"137 Kim M, Chung SR, Jeon MJ, Han M, Lee JH, et al. (2019) Determining whether tumor volume doubling time and growth rate can predict malignancy after delayed diagnostic surgery of follicular neoplasm. Thyroid 29: 1418\u20131424.","DOI":"10.1089\/thy.2019.0017"},{"key":"137","doi-asserted-by":"crossref","unstructured":"138 Hirokawa M, Suzuki A, Kawakami M, Kudo T, Miyauchi A (2022) Criteria for follow-up of thyroid nodules diagnosed as follicular neoplasm without molecular testing\u2014The experience of a high-volume thyroid centre in Japan. Diagn Cytopathol 50: 223\u2013229.","DOI":"10.1002\/dc.24937"},{"key":"138","doi-asserted-by":"crossref","unstructured":"139 Carty SE, Ohori NP, Hilko DA, McCoy KL, French EK, et al. (2020) The clinical utility of molecular testing in the management of thyroid follicular neoplasms (Bethesda IV Nodules). Ann Surg 272: 621\u2013627.","DOI":"10.1097\/SLA.0000000000004130"},{"key":"139","doi-asserted-by":"publisher","unstructured":"140 Shimbashi W, Sugitani I, Kawabata K, Mitani H, Toda K, et al. (2018) Thick tumor capsule is a valuable risk factor for distant metastasis in follicular thyroid carcinoma. Auris Nasus Larynx 45: 147\u2013155.","DOI":"10.1016\/j.anl.2017.05.002"},{"key":"140","doi-asserted-by":"crossref","unstructured":"141 Ito Y, Hirokawa M, Masuoka H, Yabuta T, Kihara M, et al. (2013) Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocr J 60: 637\u2013642.","DOI":"10.1507\/endocrj.EJ12-0419"},{"key":"141","doi-asserted-by":"crossref","unstructured":"142 Kim HJ, Sung JY, Oh YL, Kim JH, Son YI, et al. (2014) Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck 36: 1695\u20131700.","DOI":"10.1002\/hed.23511"},{"key":"142","doi-asserted-by":"publisher","unstructured":"143 Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, et al. (2011) Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid 21: 751\u2013757.","DOI":"10.1089\/thy.2010.0353"},{"key":"143","doi-asserted-by":"publisher","unstructured":"144 Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, et al. (2012) Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma. Thyroid 22: 798\u2013804.","DOI":"10.1089\/thy.2012.0051"},{"key":"144","doi-asserted-by":"crossref","unstructured":"145 Ito Y, Miyauchi A, Tomoda C, Hirokawa M, Kobayashi K, et al. (2014) Prognostic significance of patient age in minimally and widely invasive follicular thyroid carcinoma: investigation of three age groups. Endocr J 61: 265\u2013271.","DOI":"10.1507\/endocrj.EJ13-0512"},{"key":"145","doi-asserted-by":"crossref","unstructured":"146 Yamazaki H, Sugino K, Katoh R, Matsuzu K, Masaki C, et al. (2021) Outcomes for minimally invasive follicular thyroid carcinoma in relation to the change in age stratification in the AJCC 8th edition. Ann Surg Oncol 28: 3576\u20133583.","DOI":"10.1245\/s10434-020-09397-3"},{"key":"146","doi-asserted-by":"crossref","unstructured":"147 Yamazaki H, Katoh R, Sugino K, Matsuzu K, Masaki C, et al. (2022) Encapsulated angioinvasive follicular thyroid carcinoma: prognostic impact of the extent of vascular invasion. Ann Surg Oncol 29: 4236\u20134244.","DOI":"10.1245\/s10434-022-11401-x"},{"key":"147","doi-asserted-by":"crossref","unstructured":"148 Ito Y, Hirokawa M, Masuoka H, Higashiyama T, Kihara M, et al. (2022) Prognostic factors for follicular thyroid carcinoma: the importance of vascular invasion. Endocr J 69: 1149\u20131156.","DOI":"10.1507\/endocrj.EJ22-0077"},{"key":"148","doi-asserted-by":"crossref","unstructured":"149 Yamazaki H, Sugino K, Katoh R, Matsuzu K, Kitagawa W, et al. (2023) New insights on the importance of the extent of vascular invasion in widely invasive follicular thyroid carcinoma. World J Surg 47: 2767\u20132775.","DOI":"10.1007\/s00268-023-07127-w"},{"key":"149","doi-asserted-by":"crossref","unstructured":"150 Sugino K, Kameyama K, Nagahama M, Kitagawa W, Shibuya H, et al. (2014) Does completion thyroidectomy improve the outcome of patients with minimally invasive follicular carcinoma of the thyroid? Ann Surg Oncol 21: 2981\u20132986.","DOI":"10.1245\/s10434-014-3734-2"},{"key":"150","doi-asserted-by":"crossref","unstructured":"151 Brauer PR, Reddy CA, Burkey BB, Lamarre ED (2021) A national comparison of postoperative outcomes in completion thyroidectomy and total thyroidectomy. Otolaryngol Head Neck Surg 164: 566\u2013573.","DOI":"10.1177\/0194599820951165"},{"key":"151","doi-asserted-by":"crossref","unstructured":"152 Sena G, Gallo G, Innaro N, Laquatra N, Tolone M, et al. (2019) Total thyroidectomy <i>vs.<\/i> completion thyroidectomy for thyroid nodules with indeterminate cytology\/follicular proliferation: a single-centre experience. BMC Surg 19: 87.","DOI":"10.1186\/s12893-019-0552-2"},{"key":"152","doi-asserted-by":"crossref","unstructured":"153 Minni A, Rosati D, Cavaliere C, Ralli M, Sementilli G, et al. (2021) Total <i>versus<\/i> completion thyroidectomy: a multidimensional evaluation of long-term vocal alterations. Ear Nose Throat J 100: 562s\u2013568s.","DOI":"10.1177\/0145561319886156"},{"key":"153","doi-asserted-by":"crossref","unstructured":"154 Caturegli P, Ruggere C (2005) Karl H\u00fcrthle! Now, who was he? Thyroid 15: 121\u2013123.","DOI":"10.1089\/thy.2005.15.121"},{"key":"154","doi-asserted-by":"crossref","unstructured":"155 Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, et al. (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33: 27\u201363.","DOI":"10.1007\/s12022-022-09707-3"},{"key":"155","doi-asserted-by":"crossref","unstructured":"156 Coca-Pelaz A, Rodrigo JP, Shah JP, Sanabria A, Al Ghuzlan A, et al. (2021) Hurthle cell carcinoma of the thyroid gland: systematic review and meta-analysis. Adv Ther 38: 5144\u20135164.","DOI":"10.1007\/s12325-021-01876-7"},{"key":"156","doi-asserted-by":"crossref","unstructured":"157 Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, et al. (2013) Does H\u00fcrthle cell carcinoma of the thyroid have a poorer prognosis than ordinary follicular thyroid carcinoma? Ann Surg Oncol 20: 2944\u20132950.","DOI":"10.1245\/s10434-013-2965-y"},{"key":"157","doi-asserted-by":"crossref","unstructured":"158 Ito Y, Hirokawa M, Miyauchi A, Kihara M, Yabuta T, et al. (2016) Diagnosis and surgical indications of oxyphilic follicular tumors in Japan: surgical specimens and cytology. Endocr J 63: 977\u2013982.","DOI":"10.1507\/endocrj.EJ16-0268"},{"key":"158","doi-asserted-by":"crossref","unstructured":"159 Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, et al. (2003) Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97: 1186\u20131194.","DOI":"10.1002\/cncr.11176"},{"key":"159","doi-asserted-by":"crossref","unstructured":"160 Kushchayeva Y, Duh QY, Kebebew E, D\u2019Avanzo A, Clark OH (2008) Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg 195: 457\u2013462.","DOI":"10.1016\/j.amjsurg.2007.06.001"},{"key":"160","doi-asserted-by":"crossref","unstructured":"161 Kim WG, Kim TY, Kim TH, Jang HW, Jo YS, et al. (2014) Follicular and Hurthle cell carcinoma of the thyroid in iodine-sufficient area: retrospective analysis of Korean multicenter data. Korean J Intern Med 29: 325\u2013333.","DOI":"10.3904\/kjim.2014.29.3.325"},{"key":"161","doi-asserted-by":"crossref","unstructured":"162 Kushchayeva Y, Duh QY, Kebebew E, Clark OH (2004) Prognostic indications for Hurthle cell cancer. World J Surg 28: 1266\u20131270.","DOI":"10.1007\/s00268-004-7602-2"},{"key":"162","doi-asserted-by":"publisher","unstructured":"163 Nagar S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Grogan RH (2013) Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery 154: 1263\u20131271.","DOI":"10.1016\/j.surg.2013.06.029"},{"key":"163","doi-asserted-by":"publisher","unstructured":"164 Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, et al. (2005) Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 115: 1445\u20131450.","DOI":"10.1097\/01.mlg.0000168114.90852.a6"},{"key":"164","doi-asserted-by":"crossref","unstructured":"165 Kotwal A, Erickson D, Geske JR, Hay ID, Castro MR (2021) Predicting outcomes in sporadic and hereditary medullary thyroid carcinoma over two decades. Thyroid 31: 616\u2013626.","DOI":"10.1089\/thy.2020.0167"},{"key":"165","doi-asserted-by":"crossref","unstructured":"166 Esfandiari NH, Hughes DT, Yin HY, Banerjee M, Haymart MR (2014) The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab 99: 448\u2013454.","DOI":"10.1210\/jc.2013-2942"},{"key":"166","doi-asserted-by":"publisher","unstructured":"167 Kuo EJ, Sho SN, Li N, Zanocco KA, Yeh MW, et al. (2018) Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surgery 153: 52\u201359.","DOI":"10.1001\/jamasurg.2017.3555"},{"key":"167","doi-asserted-by":"crossref","unstructured":"168 Ito Y, Miyauchi A, Kihara M, Higashiiyama T, Fukushima M, et al. (2018) Static prognostic factors and appropriate surgical designs for patients with medullary thyroid carcinoma: the second report from a single-institution study in Japan. World J Surg 42: 3954\u20133966.","DOI":"10.1007\/s00268-018-4738-z"},{"key":"168","doi-asserted-by":"crossref","unstructured":"169 Jiao Z, Wu T, Jiang MJ, Jiang SX, Jiang K, et al. (2022) Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: a retrospective study. Front Endocrinol (Lausanne) 13: 1094242.","DOI":"10.3389\/fendo.2022.1094242"},{"key":"169","doi-asserted-by":"crossref","unstructured":"170 Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, et al. (2022) International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J Clin Oncol 40: 96\u2013104.","DOI":"10.1200\/JCO.21.01329"},{"key":"170","doi-asserted-by":"crossref","unstructured":"171 Nigam A, Xu B, Spanheimer PM, Ganly I, Tuttle RM, et al. (2022) Tumor grade predicts for calcitonin doubling times and disease-specific outcomes after resection of medullary thyroid carcinoma. Thyroid 32: 1193\u20131200.","DOI":"10.1089\/thy.2022.0217"},{"key":"171","doi-asserted-by":"crossref","unstructured":"172 Censi S, Manso J, Mian C (2023) Other markers of medullary thyroid cancer, not only calcitonin. Eur J Endocrinol 188: lvac009.","DOI":"10.1093\/ejendo\/lvac009"},{"key":"172","doi-asserted-by":"crossref","unstructured":"173 Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, et al. (2022) Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20: 925\u2013951.","DOI":"10.6004\/jnccn.2022.0040"},{"key":"173","unstructured":"174 Miyauchi A, Onishi T, Matsuzuka F, Hirai K, Kuma K, et al. (1986) Prognostic values of the doubling time of serum carcinoembryonic antigen and calcitonin levels in medullary thyroid carcinoma. Gan No Rinsho 32: 1519\u20131524 (In Japanese)."},{"key":"174","doi-asserted-by":"crossref","unstructured":"175 Miyauchi A, Kudo T, Kihara M, Oda H, Ito Y, et al. (2019) Spontaneous deceleration and acceleration of growth rate in medullary thyroid carcinomas suggested by changes in calcitonin doubling times over long-term surveillance. World J Surg 43: 504\u2013512.","DOI":"10.1007\/s00268-018-4789-1"},{"key":"175","doi-asserted-by":"crossref","unstructured":"176 Parkhurst E, Calonico E, Abboy S (2018) Utilization of genetic testing for mutations in patients with medullary thyroid carcinoma: a single-center experience. J Genet Couns 27: 1411\u20131416.","DOI":"10.1007\/s10897-018-0273-1"},{"key":"176","doi-asserted-by":"crossref","unstructured":"177 Mathiesen JS, Effraimidis G, Rossing M, Rasmussen \u00c5K, Hoejberg L, et al. (2022) Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol 79: 163\u2013179.","DOI":"10.1016\/j.semcancer.2021.03.035"},{"key":"177","doi-asserted-by":"crossref","unstructured":"178 Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, et al. (2013) High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line codon 634 mutation in Japanese patients. Eur J Endocrinol 168: 683\u2013687.","DOI":"10.1530\/EJE-12-1106"},{"key":"178","doi-asserted-by":"crossref","unstructured":"179 Skinner MA, Moley JA, Dilley WG, Owzar K, DeBenedetti MK, et al. (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353: 1105\u20131113.","DOI":"10.1056\/NEJMoa043999"},{"key":"179","doi-asserted-by":"publisher","unstructured":"180 Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, et al. (2015) Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma. Thyroid 25: 567\u2013610.","DOI":"10.1089\/thy.2014.0335"},{"key":"180","doi-asserted-by":"publisher","unstructured":"181 Beressi N, Campos JM, Beressi JP, Franc B, Niccoli-Sire P, et al. (1998) Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid 8: 1039\u20131044.","DOI":"10.1089\/thy.1998.8.1039"},{"key":"181","doi-asserted-by":"publisher","unstructured":"182 Kihara M (2017) Prophylactic total thyroidectomy in RET gene mutation carriers. Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery 34: 41\u201344 (In Japanese).","DOI":"10.11226\/jaesjsts.34.1_41"},{"key":"182","doi-asserted-by":"crossref","unstructured":"183 Kluijfhout WP, van Beek DJ, Verrijn Stuart AA, Lodewijk L, Valk GD, et al. (2015) Postoperative complications after prophylactic thyroidectomy for very young patients with multiple endocrine neoplasia type 2 retrospective cohort analysis. Medicine (Baltimore) 94: e1108.","DOI":"10.1097\/MD.0000000000001108"},{"key":"183","doi-asserted-by":"crossref","unstructured":"184 Matsushita R, Nagasaki K, Ayabe T, Miyoshi Y, Kinjo S, et al. (2019) Present status of prophylactic thyroidectomy in pediatric multiple endocrine neoplasia 2: a nationwide survey in Japan 1997\u20132017. J Pediatr Endocrinol Metab 32: 585\u2013595.","DOI":"10.1515\/jpem-2018-0444"},{"key":"184","doi-asserted-by":"crossref","unstructured":"185 Pillarisetty VG, Katz SC, Ghossein RA, Tuttle RM, Shaha AR (2009) Micromedullary thyroid cancer: how micro is truly micro? Ann Surg Oncol 16: 2875\u20132881.","DOI":"10.1245\/s10434-009-0595-1"},{"key":"185","doi-asserted-by":"crossref","unstructured":"186 Zhang JM, Gu PF, Huang DM, Zhao JZ, Zheng XQ, et al. (2022) Surgical selection and prognostic analysis in patients with unilateral sporadic medullary thyroid carcinoma. Langenbecks Arch Surg 407: 3013\u20133023.","DOI":"10.1007\/s00423-022-02591-9"},{"key":"186","doi-asserted-by":"crossref","unstructured":"187 Kihara M, Miyauchi A, Yoshioka K, Oda H, Nakayama A, et al. (2016) Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: a single institution experience. Auris Nasus Larynx 43: 551\u2013555.","DOI":"10.1016\/j.anl.2015.12.016"},{"key":"187","doi-asserted-by":"crossref","unstructured":"188 Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, et al. (2002) Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline mutations. World J Surg 26: 1023\u20131028.","DOI":"10.1007\/s00268-002-6665-1"},{"key":"188","unstructured":"189 Ma SH, Liu QJ, Zhang YC, Yang R (2011) Alternative surgical strategies in patients with sporadic medullary thyroid carcinoma: long-term follow-up. Oncol Lett 2: 975\u2013980."},{"key":"189","doi-asserted-by":"crossref","unstructured":"190 Essig GF, Porter K, Schneider D, Arpaia D, Lindsey SC, et al. (2016) Multifocality in sporadic medullary thyroid carcinoma: an international multicenter study. Thyroid 26: 1563\u20131572.","DOI":"10.1089\/thy.2016.0255"},{"key":"190","doi-asserted-by":"crossref","unstructured":"191 Szabo Yamashita T, Rogers RT, Foster TR, Lyden ML, Morris JC, et al. (2022) Medullary thyroid cancer: What is the optimal management of the lateral neck in a node negative patient at index operation? Surgery 171: 177\u2013181.","DOI":"10.1016\/j.surg.2021.04.052"},{"key":"191","doi-asserted-by":"crossref","unstructured":"192 Spanheimer PM, Ganly I, Chou JF, Capanu M, Nigam A, et al. (2021) Prophylactic lateral neck dissection for medullary thyroid carcinoma is not associated with improved survival. Ann Surg Oncol 28: 6572\u20136579.","DOI":"10.1245\/s10434-021-09683-8"},{"key":"192","doi-asserted-by":"crossref","unstructured":"193 Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, et al. (2018) Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck 40: 79\u201385.","DOI":"10.1002\/hed.24969"},{"key":"193","doi-asserted-by":"crossref","unstructured":"194 van Beek DJ, Almquist M, Bergenfelz AO, Musholt TJ, Nordenstr\u00f6m E, et al. (2021) Complications after medullary thyroid carcinoma surgery: multicentre study of the SQRTPA and EUROCRINE<sup>\u00ae<\/sup> databases. Br J Surg 108: 691\u2013701.","DOI":"10.1093\/bjs\/znaa195"},{"key":"194","doi-asserted-by":"publisher","unstructured":"195 Sakamoto A, Kasai N, Sugano H (1983) Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52: 1849\u20131855.","DOI":"10.1002\/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X"},{"key":"195","doi-asserted-by":"crossref","unstructured":"196 Carcangiu ML, Zamp G, Rosai J (1984) Poorly differentiated (\u201cinsular\u201d) thyroid carcinoma: a reinterpretation of Langhans\u2019 \u201cwuchernde Struma\u201d. Am J Surg Pathol 8: 655\u2013668.","DOI":"10.1097\/00000478-198409000-00005"},{"key":"196","doi-asserted-by":"crossref","unstructured":"197 Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, et al. (2007) Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31: 1256\u20131264.","DOI":"10.1097\/PAS.0b013e3180309e6a"},{"key":"197","doi-asserted-by":"crossref","unstructured":"198 Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, et al. (2006) Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106: 1286\u20131295.","DOI":"10.1002\/cncr.21739"},{"key":"198","doi-asserted-by":"crossref","unstructured":"199 Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292\u2013306.","DOI":"10.1038\/nrc1836"},{"key":"199","doi-asserted-by":"crossref","unstructured":"200 Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, et al. (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126: 1052\u20131066.","DOI":"10.1172\/JCI85271"},{"key":"200","doi-asserted-by":"crossref","unstructured":"201 Akaishi J, Kondo T, Sugino K, Ogimi Y, Masaki C, et al. (2019) Prognostic impact of the Turin criteria in poorly differentiated thyroid carcinoma. World J Surg 43: 2235\u20132244.","DOI":"10.1007\/s00268-019-05028-5"},{"key":"201","doi-asserted-by":"crossref","unstructured":"202 Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, et al. (2007) Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. World J Surg 31: 1417\u20131424.","DOI":"10.1007\/s00268-007-9095-2"},{"key":"202","doi-asserted-by":"crossref","unstructured":"203 Ito Y, Hirokawa M, Fukushima M, Inoue H, Yabuta T, et al. (2008) Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg 32: 1535\u20131543; discussion 1544\u20131545.","DOI":"10.1007\/s00268-007-9406-7"},{"key":"203","doi-asserted-by":"crossref","unstructured":"204 Nunes da Silva T, Limbert E, Leite V (2018) Poorly differentiated thyroid carcinoma patients with detectable thyroglobulin levels after initial treatment show an increase in mortality and disease recurrence. Eur Thyroid J 7: 313\u2013318.","DOI":"10.1159\/000491996"},{"key":"204","doi-asserted-by":"crossref","unstructured":"205 Thiagarajan S, Yousuf A, Shetty R, Dhar H, Mathur Y, et al. (2020) Poorly differentiated thyroid carcinoma (PDTC) characteristics and the efficacy of radioactive iodine (RAI) therapy as an adjuvant treatment in a tertiary cancer care center. Eur Arch Otorhinolaryngol 277: 1807\u20131814.","DOI":"10.1007\/s00405-020-05898-9"},{"key":"205","doi-asserted-by":"crossref","unstructured":"206 Lee DY, Won JK, Lee SH, Park DJ, Jung KC, et al. (2016) Changes of clinicopathologic characteristics and survival outcomes of anaplastic and poorly differentiated thyroid carcinoma. Thyroid 26: 404\u2013413.","DOI":"10.1089\/thy.2015.0316"},{"key":"206","doi-asserted-by":"crossref","unstructured":"207 Yu MG, Rivera J, Jimeno C (2017) Poorly differentiated thyroid carcinoma: 10-year experience in a Southeast Asian population. Endocrinol Metab (Seoul) 32: 288\u2013295.","DOI":"10.3803\/EnM.2017.32.2.288"},{"key":"207","doi-asserted-by":"publisher","unstructured":"208 Ibrahimpasic T, Ghossein R, Carlson DL, Chernichenko N, Nixon I, et al. (2013) Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986\u20132009 Memorial Sloan-Kettering Cancer Center experience. Thyroid 23: 997\u20131002.","DOI":"10.1089\/thy.2012.0403"},{"key":"208","doi-asserted-by":"crossref","unstructured":"209 Ibrahimpasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, et al. (2014) Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab 99: 1245\u20131252.","DOI":"10.1210\/jc.2013-3842"},{"key":"209","doi-asserted-by":"crossref","unstructured":"210 de la Fouchardiere C, Decaussin-Petrucci M, Berthiller J, Descotes F, Lopez J, et al. (2018) Predictive factors of outcome in poorly differentiated thyroid carcinomas. Eur J Cancer 92: 40\u201347.","DOI":"10.1016\/j.ejca.2017.12.027"},{"key":"210","doi-asserted-by":"crossref","unstructured":"211 Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25: 617\u2013622.","DOI":"10.1007\/s002680020166"},{"key":"211","doi-asserted-by":"crossref","unstructured":"212 Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, et al. (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort study of 677 patients. World J Surg 36: 1247\u20131254.","DOI":"10.1007\/s00268-012-1437-z"},{"key":"212","doi-asserted-by":"publisher","unstructured":"213 Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, et al. (2016) The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid 26: 1293\u20131299.","DOI":"10.1089\/thy.2016.0072"},{"key":"213","doi-asserted-by":"crossref","unstructured":"214 Higashiyama T, Sugino K, Hara H, Ito KI, Nakashima N, et al. (2022) Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer 173: 210\u2013218.","DOI":"10.1016\/j.ejca.2022.06.044"},{"key":"214","doi-asserted-by":"crossref","unstructured":"215 Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, et al. (2020) Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol 6: 1397\u20131404.","DOI":"10.1001\/jamaoncol.2020.3362"},{"key":"215","doi-asserted-by":"crossref","unstructured":"216 Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, et al. (2023) Surgery after BRAF-directed therapy is associated with improved survival in BRAF(V600E) mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid 33: 484\u2013491.","DOI":"10.1089\/thy.2022.0504"},{"key":"216","doi-asserted-by":"publisher","unstructured":"217 Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, et al. (2011) Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21: 1183\u20131189.","DOI":"10.1089\/thy.2010.0332"},{"key":"217","doi-asserted-by":"crossref","unstructured":"218 Han JM, Bae Kim W, Kim TY, Ryu JS, Gong G, et al. (2012) Time trend in tumour size and characteristics of anaplastic thyroid carcinoma. Clin Endocrinol (Oxf) 77: 459\u2013464.","DOI":"10.1111\/j.1365-2265.2012.04396.x"},{"key":"218","doi-asserted-by":"crossref","unstructured":"219 Yoshida A, Sugino K, Sugitani I, Miyauchi A (2014) Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination. World J Surg 38: 2311\u20132316.","DOI":"10.1007\/s00268-014-2536-9"},{"key":"219","doi-asserted-by":"crossref","unstructured":"220 Greenberg JA, Moore MD, Thiesmeyer JW, Egan CE, Lee YJ, et al. (2023) Coexisting papillary and anaplastic thyroid cancer: elucidating the spectrum of aggressive behavior. Ann Surg Oncol 30: 137\u2013145.","DOI":"10.1245\/s10434-022-12553-6"},{"key":"220","doi-asserted-by":"publisher","unstructured":"221 Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, et al. (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20: 7\u201314.","DOI":"10.1089\/thy.2009.0115"},{"key":"221","doi-asserted-by":"crossref","unstructured":"222 Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, et al. (2019) Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 29: 1036\u20131043.","DOI":"10.1089\/thy.2019.0133"},{"key":"222","doi-asserted-by":"crossref","unstructured":"223 Machens A, Hinze R, Lautenschlager C, Thomusch O, Dunst J, et al. (2001) Extended surgery and early postoperative radiotherapy for undifferentiated thyroid carcinoma. Thyroid 11: 373\u2013380.","DOI":"10.1089\/10507250152039127"},{"key":"223","doi-asserted-by":"crossref","unstructured":"224 Brown RF, Ducic Y (2013) Aggressive surgical resection of anaplastic thyroid carcinoma may provide long-term survival in selected patients. Otolaryngol Head Neck Surg 148: 564\u2013571.","DOI":"10.1177\/0194599813477364"},{"key":"224","doi-asserted-by":"crossref","unstructured":"225 Sugitani I, Hasegawa Y, Sugasawa M, Tori M, Higashiyama T, et al. (2014) Super-radical surgery for anaplastic thyroid carcinoma: a large cohort study using the Anaplastic Thyroid Carcinoma Research Consortium of Japan database. Head Neck 36: 328\u2013333.","DOI":"10.1002\/hed.23295"},{"key":"225","doi-asserted-by":"crossref","unstructured":"226 McCrary HC, Aoki J, Huang Y, Chadwick B, Kerrigan K, et al. (2022) Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol (Oxf) 96: 734\u2013742.","DOI":"10.1111\/cen.14679"},{"key":"226","doi-asserted-by":"crossref","unstructured":"227 Kent J, Erwin P, Haraf D, Liao CY, Durham J, et al. (2023) Laryngotracheal resection after B-raf proto-oncogene inhibition for anaplastic thyroid carcinoma. Ann Thorac Surg 115: e117\u2013e120.","DOI":"10.1016\/j.athoracsur.2022.04.034"},{"key":"227","doi-asserted-by":"crossref","unstructured":"228 Saeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, et al. (2020) Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head Neck 42: 1031\u20131044.","DOI":"10.1002\/hed.26086"},{"key":"228","doi-asserted-by":"crossref","unstructured":"229 Kwon J, Kim BH, Jung HW, Besic N, Sugitani I, et al. (2016) The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and meta-analysis. Eur J Cancer 59: 34\u201345.","DOI":"10.1016\/j.ejca.2016.02.015"},{"key":"229","doi-asserted-by":"publisher","unstructured":"230 Haugen BR AE, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. (2016) 2015 Amreican Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyrodi nodules and differentiated thryoid cancer. Thyroid 26: 1\u2013133.","DOI":"10.1089\/thy.2015.0020"},{"key":"230","doi-asserted-by":"crossref","unstructured":"231 Pacini F, Fuhrer D, Elisei R, Handkiewicz-Junak D, Leboulleux S, et al. (2022) 2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J 11: e210046.","DOI":"10.1530\/ETJ-21-0046"},{"key":"231","doi-asserted-by":"crossref","unstructured":"232 Sparano C, Moog S, Hadoux J, Dupuy C, Al Ghuzlan A, et al. (2022) Strategies for radioiodine treatment: what\u2019s new. Cancers (Basel) 14: 3800.","DOI":"10.3390\/cancers14153800"},{"key":"232","doi-asserted-by":"crossref","unstructured":"233 Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, et al. (2012) Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 366: 1663\u20131673.","DOI":"10.1056\/NEJMoa1108586"},{"key":"233","doi-asserted-by":"crossref","unstructured":"234 Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, et al. (2012) Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 366: 1674\u20131685.","DOI":"10.1056\/NEJMoa1109589"},{"key":"234","doi-asserted-by":"crossref","unstructured":"235 Nascimento C, Borget I, Troalen F, Al Ghuzlan A, Deandreis D, et al. (2013) Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur J Endocrinol 169: 689\u2013693.","DOI":"10.1530\/EJE-13-0386"},{"key":"235","doi-asserted-by":"crossref","unstructured":"236 Nakabashi CC, Kasamatsu TS, Crispim F, Yamazaki CA, Camacho CP, et al. (2014) Basal serum thyroglobulin measured by a second-generation assay is equivalent to stimulated thyroglobulin in identifying metastases in patients with differentiated thyroid cancer with low or intermediate risk of recurrence. Eur Thyroid J 3: 43\u201350.","DOI":"10.1159\/000360077"},{"key":"236","doi-asserted-by":"crossref","unstructured":"237 Kashat L, Orlov S, Orlov D, Assi J, Salari F, et al. (2016) Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk PTC patients not receiving radioactive iodine. Endocrine 54: 460\u2013466.","DOI":"10.1007\/s12020-016-0989-3"},{"key":"237","doi-asserted-by":"crossref","unstructured":"238 Rosario PW, Mour\u00e3o GF, Calsolari MR (2016) Can the follow-up of patients with PTC of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays? Clin Endocrinol (Oxf) 85: 596\u2013601.","DOI":"10.1111\/cen.13053"},{"key":"238","doi-asserted-by":"crossref","unstructured":"239 Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, et al. (2022) Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med 386: 923\u2013932.","DOI":"10.1056\/NEJMoa2111953"},{"key":"239","doi-asserted-by":"crossref","unstructured":"240 Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, et al. (2005) rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12: 49\u201364.","DOI":"10.1677\/erc.1.00830"},{"key":"240","doi-asserted-by":"crossref","unstructured":"241 Watanabe K, Igarashi T, Uchiyama M, Ojiri H (2020) Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin. Ann Nucl Med 34: 920\u2013925.","DOI":"10.1007\/s12149-020-01523-1"},{"key":"241","doi-asserted-by":"crossref","unstructured":"242 Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, et al. (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91: 926\u2013932.","DOI":"10.1210\/jc.2005-1651"},{"key":"242","doi-asserted-by":"crossref","unstructured":"243 Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, et al. (2019) Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol 7: 44\u201351.","DOI":"10.1016\/S2213-8587(18)30306-1"},{"key":"243","doi-asserted-by":"crossref","unstructured":"244 Jeong SY, Lee SW, Kim WW, Jung JH, Lee WK, et al. (2019) Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy. Sci Rep 9: 5570.","DOI":"10.1038\/s41598-019-42083-3"},{"key":"244","doi-asserted-by":"crossref","unstructured":"245 Rosario PW, Mour\u00e3o GF, Calsolari MR (2017) Recombinant human TSH <i>versus<\/i> thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with PTC and clinically apparent lymph node metastases not limited to the central compartment (cN1b). Arch Endocrinol Metab 61: 167\u2013172.","DOI":"10.1590\/2359-3997000000247"},{"key":"245","doi-asserted-by":"crossref","unstructured":"246 Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM (2012) Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid 22: 1007\u20131015.","DOI":"10.1089\/thy.2012.0183"},{"key":"246","doi-asserted-by":"crossref","unstructured":"247 Gomes-Lima CJ, Chittimoju S, Wehbeh L, Dia S, Pagadala P, et al. (2022) Metastatic differentiated thyroid cancer survival is unaffected by mode of preparation for (131)I administration. J Endocr Soc 6: bvac032.","DOI":"10.1210\/jendso\/bvac032"},{"key":"247","doi-asserted-by":"crossref","unstructured":"248 Sim\u00f5es-Pereira J, Ferreira TC, Limbert E, Cavaco BM, Leite V (2021) Outcomes of thyrotropin alfa <i>versus<\/i> levothyroxine withdrawal-aided radioiodine therapy for distant metastasis of papillary thyroid cancer. Thyroid 31: 1514\u20131522.","DOI":"10.1089\/thy.2021.0013"},{"key":"248","doi-asserted-by":"crossref","unstructured":"249 Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM (2011) Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab 96: 2105\u20132111.","DOI":"10.1210\/jc.2011-0305"},{"key":"249","doi-asserted-by":"crossref","unstructured":"250 Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, et al. (2012) Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal <i>versus<\/i> recombinant human thyrotropin. Thyroid 22: 310\u2013317.","DOI":"10.1089\/thy.2011.0235"},{"key":"250","doi-asserted-by":"crossref","unstructured":"251 Borget I, Bonastre J, Catargi B, D\u00e9andr\u00e9is D, Zerdoud S, et al. (2015) Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. J Clin Oncol 33: 2885\u20132892.","DOI":"10.1200\/JCO.2015.61.6722"},{"key":"251","doi-asserted-by":"crossref","unstructured":"252 Klain M, Nappi C, Zampella E, Cantoni V, Green R, et al. (2021) Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging 48: 4437\u20134444.","DOI":"10.1007\/s00259-021-05440-x"},{"key":"252","doi-asserted-by":"crossref","unstructured":"253 Abe K, Ishizaki U, Ono T, Horiuchi K, Kanaya K, et al. (2020) Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer. Ann Nucl Med 34: 144\u2013151.","DOI":"10.1007\/s12149-019-01432-y"},{"key":"253","doi-asserted-by":"crossref","unstructured":"254 Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, et al. (2014) Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Thyroid 24: 820\u2013825.","DOI":"10.1089\/thy.2013.0362"},{"key":"254","doi-asserted-by":"crossref","unstructured":"255 Qu Y, Huang R, Li L (2017) Low- and high-dose radioiodine therapy for low-\/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial. Ann Nucl Med 31: 71\u201383.","DOI":"10.1007\/s12149-016-1133-4"},{"key":"255","doi-asserted-by":"crossref","unstructured":"256 Cheng W, Ma C, Fu H, Li J, Chen S, et al. (2013) Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J Clin Endocrinol Metab 98: 1353\u20131360.","DOI":"10.1210\/jc.2012-3682"},{"key":"256","doi-asserted-by":"crossref","unstructured":"257 Horvath E, Skoknic V, Majlis S, Tala H, Silva C, et al. (2020) Radioiodine-induced salivary gland damage detected by US in patients treated for papillary thyroid cancer: radioactive iodine activity and risk. Thyroid 30: 1646\u20131655.","DOI":"10.1089\/thy.2019.0563"},{"key":"257","unstructured":"258 Van Nostrand D, Neutze J, Atkins F (1986) Side effects of \u201crational dose\u201d iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27: 1519\u20131527."},{"key":"258","doi-asserted-by":"crossref","unstructured":"259 Noaparast Z, Hosseinimehr SJ (2013) Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy. Future Oncol 9: 1145\u20131159.","DOI":"10.2217\/fon.13.79"},{"key":"259","doi-asserted-by":"crossref","unstructured":"260 Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, et al. (2002) Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging 29: 1428\u20131432.","DOI":"10.1007\/s00259-002-0969-0"},{"key":"260","unstructured":"261 Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, et al. (2003) Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 44: 451\u2013456."},{"key":"261","doi-asserted-by":"crossref","unstructured":"262 Bourcigaux N, Rubino C, Berthaud I, Toubert ME, Donadille B, et al. (2018) Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. Hum Reprod 33: 1408\u20131416.","DOI":"10.1093\/humrep\/dey222"},{"key":"262","doi-asserted-by":"crossref","unstructured":"263 Hyer S, Vini L, O\u2019Connell M, Pratt B, Harmer C (2002) Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 56: 755\u2013758.","DOI":"10.1046\/j.1365-2265.2002.t01-1-01545.x"},{"key":"263","unstructured":"264 Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, et al. (1996) Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37: 606\u2013612."},{"key":"264","doi-asserted-by":"crossref","unstructured":"265 Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, et al. (2008) A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 69: 479\u2013490.","DOI":"10.1111\/j.1365-2265.2008.03222.x"},{"key":"265","doi-asserted-by":"crossref","unstructured":"266 Pasqual E, Schonfeld S, Morton LM, Villoing D, Lee C, et al. (2022) Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies. J Clin Oncol 40: 1439\u20131449.","DOI":"10.1200\/JCO.21.01841"},{"key":"266","doi-asserted-by":"crossref","unstructured":"267 Zhao X, Chen M, Qi X, Zhu H, Yang G, et al. (2021) Association of radioiodine for differentiated thyroid cancer and second breast cancer in female adolescent and young adult. Front Endocrinol (Lausanne) 12: 805194.","DOI":"10.3389\/fendo.2021.805194"},{"key":"267","doi-asserted-by":"crossref","unstructured":"268 Nappi C, Klain M, Cantoni V, Green R, Piscopo L, et al. (2022) Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 49: 1630\u20131639.","DOI":"10.1007\/s00259-021-05625-4"},{"key":"268","doi-asserted-by":"crossref","unstructured":"269 Kim S, Bang JI, Boo D, Kim B, Choi IY, et al. (2022) Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. Eur J Nucl Med Mol Imaging 49: 3547\u20133556.","DOI":"10.1007\/s00259-022-05779-9"},{"key":"269","doi-asserted-by":"crossref","unstructured":"270 Fundakowski CE, Hales NW, Agrawal N, Barczynski M, Camacho PM, et al. (2018) Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. Head Neck 40: 663\u2013675.","DOI":"10.1002\/hed.24928"},{"key":"270","doi-asserted-by":"crossref","unstructured":"271 Kumai Y, Kodama N, Murakami D, Yumoto E (2016) Comparison of vocal outcome following two different procedures for immediate RLN reconstruction. Eur Arch Otorhinolaryngol 273: 967\u2013972.","DOI":"10.1007\/s00405-015-3852-x"},{"key":"271","first-page":"S18","volume":"128","author":"CW Wu","year":"2018","unstructured":"272 Wu CW, Dionigi G, Barczynski M, Chiang FY, Dralle H, et al. (2018) International neuromonitoring study group guidelines 2018: Part II: Optimal recurrent laryngeal nerve management for invasive thyroid cancer-incorporation of surgical, laryngeal, and neural electrophysiologic data. Laryngoscope 128 Suppl 3: S18\u2013S27.","journal-title":"The Laryngoscope","ISSN":"https:\/\/id.crossref.org\/issn\/0023-852X","issn-type":"print"},{"key":"272","doi-asserted-by":"crossref","unstructured":"273 Kamani D, Darr EA, Randolph GW (2013) Electrophysiologic monitoring characteristics of the recurrent laryngeal nerve preoperatively paralyzed or invaded with malignancy. Otolaryngol Head Neck Surg 149: 682\u2013688.","DOI":"10.1177\/0194599813504735"},{"key":"273","doi-asserted-by":"crossref","unstructured":"274 Kihara M, Miyauchi A, Yabuta T, Higashiyama T, Fukushima M, et al. (2014) Outcome of vocal cord function after partial layer resection of the recurrent laryngeal nerve in patients with invasive papillary thyroid cancer. Surgery 155: 184\u2013189.","DOI":"10.1016\/j.surg.2013.06.052"},{"key":"274","doi-asserted-by":"crossref","unstructured":"275 Lee HS, Kim SW, Park T, Nam GY, Hong JC, et al. (2015) PTC with exclusive involvement of a functioning recurrent laryngeal nerve may be treated with shaving technique. World J Surg 39: 969\u2013974.","DOI":"10.1007\/s00268-014-2906-3"},{"key":"275","doi-asserted-by":"publisher","unstructured":"276 Moritani S, Takenobu M, Yoshioka K, Kawamoto K, Fujii T, et al. (2021) Novel surgical methods for reconstruction of the recurrent laryngeal nerve: microscope-guided partial layer resection and intralaryngeal reconstruction of the recurrent laryngeal nerve. Surgery 169: 1124\u20131130.","DOI":"10.1016\/j.surg.2020.09.017"},{"key":"276","doi-asserted-by":"crossref","unstructured":"277 Nishida T, Nakao K, Hamaji M, Kamiike W, Kurozumi K, et al. (1997) Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer. Ann Surg 226: 85\u201391.","DOI":"10.1097\/00000658-199707000-00012"},{"key":"277","doi-asserted-by":"crossref","unstructured":"278 Lang BH, Lo CY, Wong KP, Wan KY (2013) Should an involved but functioning recurrent laryngeal nerve be shaved or resected in a locally advanced PTC? Ann Surg Oncol 20: 2951\u20132957.","DOI":"10.1245\/s10434-013-2984-8"},{"key":"278","doi-asserted-by":"crossref","unstructured":"279 Miyamaru S, Kumai Y, Murakami D, Kodama N, Miyamoto T, et al. (2019) Phonatory function in patients with well-differentiated thyroid carcinoma following meticulous resection of tumors adhering to the recurrent laryngeal nerve. Int J Clin Oncol 24: 1536\u20131542.","DOI":"10.1007\/s10147-019-01496-w"},{"key":"279","doi-asserted-by":"crossref","unstructured":"280 Ito Y, Kihara M, Takamura Y, Kobayashi K, Miya A, et al. (2012) Prognosis and prognostic factors of patients with PTC requiring resection of recurrent laryngeal nerve due to carcinoma extension. Endocr J 59: 247\u2013252.","DOI":"10.1507\/endocrj.EJ11-0355"},{"key":"280","doi-asserted-by":"publisher","unstructured":"281 Brooks JA, Abdelhamid Ahmed AH, Al-Qurayshi Z, Kamani D, Kyriazidis N, et al. (2022) Recurrent laryngeal nerve invasion by thyroid cancer: laryngeal function and survival outcomes. Laryngoscope 132: 2285\u20132292.","DOI":"10.1002\/lary.30115"},{"key":"281","doi-asserted-by":"crossref","unstructured":"282 Moritani S (2020) Impact of gross extrathyroidal extension into major neck structures on the prognosis of PTC according to the American Joint Committee on Cancer eighth edition. Endocr J 67: 941\u2013948.","DOI":"10.1507\/endocrj.EJ19-0523"},{"key":"282","doi-asserted-by":"crossref","unstructured":"283 Miyauchi A, Matsusaka K, Kihara M, Matsuzuka F, Hirai K, et al. (1998) The role of ansa-to-recurrent-laryngeal nerve anastomosis in operations for thyroid cancer. Eur J Surg 164: 927\u2013933.","DOI":"10.1080\/110241598750005093"},{"key":"283","doi-asserted-by":"crossref","unstructured":"284 Wang W, Liu F, Zhang C, Li M, Chen S, et al. (2020) Immediate ansa cervicalis-to-recurrent laryngeal nerve anastomosis for the management of recurrent laryngeal nerve infiltration by a differentiated thyroid carcinoma. ORL J Otorhinolaryngol Relat Spec 82: 93\u2013105.","DOI":"10.1159\/000505129"},{"key":"284","doi-asserted-by":"crossref","unstructured":"285 Iwaki S, Maeda T, Saito M, Otsuki N, Takahashi M, et al. (2017) Role of immediate recurrent laryngeal nerve reconstruction in surgery for thyroid cancers with fixed vocal cords. Head Neck 39: 427\u2013431.","DOI":"10.1002\/hed.24627"},{"key":"285","doi-asserted-by":"publisher","unstructured":"286 Yumoto E, Sanuki T, Kumai Y (2006) Immediate recurrent laryngeal nerve reconstruction and vocal outcome. Laryngoscope 116: 1657\u20131661.","DOI":"10.1097\/01.mlg.0000233245.27582.fc"},{"key":"286","doi-asserted-by":"crossref","unstructured":"287 Sanuki T, Yumoto E, Minoda R, Kodama N (2010) The role of immediate recurrent laryngeal nerve reconstruction for thyroid cancer surgery. J Oncol 2010: 846235.","DOI":"10.1155\/2010\/846235"},{"key":"287","doi-asserted-by":"crossref","unstructured":"288 Miyauchi A, Masuoka H, Tomoda C, Takamura Y, Ito Y, et al. (2012) Laryngeal approach to the recurrent laryngeal nerve involved by thyroid cancer at the ligament of Berry. Surgery 152: 57\u201360.","DOI":"10.1016\/j.surg.2011.12.033"},{"key":"288","doi-asserted-by":"crossref","unstructured":"289 Miyauchi A, Ito Y, Miya A, Higashiyama T, Tomoda C, et al. (2007) Lateral mobilization of the recurrent laryngeal nerve to facilitate tracheal surgery in patients with thyroid cancer invading the trachea near Berry\u2019s ligament. World J Surg 31: 2081\u20132084.","DOI":"10.1007\/s00268-007-9180-6"},{"key":"289","doi-asserted-by":"crossref","unstructured":"290 Shindo ML, Caruana SM, Kandil E, McCaffrey JC, Orloff LA, et al. (2014) Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement.  Head Neck 36: 1379\u20131390.","DOI":"10.1002\/hed.23619"},{"key":"290","doi-asserted-by":"crossref","unstructured":"291 Brauckhoff M, Machens A, Thanh PN, Lorenz K, Schmeil A, et al. (2010) Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival. Surgery 148: 1257\u20131266.","DOI":"10.1016\/j.surg.2010.09.011"},{"key":"291","doi-asserted-by":"crossref","unstructured":"292 Hartl DM, Zago S, Leboulleux S, Mirghani H, Deandreis D, et al. (2014) Resection margins and prognosis in locally invasive thyroid cancer. Head Neck 36: 1034\u20131038.","DOI":"10.1002\/hed.23406"},{"key":"292","doi-asserted-by":"crossref","unstructured":"293 Avenia N, Vannucci J, Monacelli M, Lucchini R, Polistena A, et al. (2016) Thyroid cancer invading the airway: diagnosis and management. Int J Surg 28 Suppl 1: S75\u2013S78.","DOI":"10.1016\/j.ijsu.2015.12.036"},{"key":"293","doi-asserted-by":"crossref","unstructured":"294 Wada N, Nakayama H, Masudo Y, Suganuma N, Rino Y (2006) Clinical outcome of different modes of resection in PTCs with laryngotracheal invasion. Langenbecks Arch Surg 391: 545\u2013549.","DOI":"10.1007\/s00423-006-0106-9"},{"key":"294","doi-asserted-by":"crossref","unstructured":"295 Ito Y, Fukushima M, Yabuta T, Tomoda C, Inoue H, et al. (2009) Local prognosis of patients with PTC who were intra-operatively diagnosed as having minimal invasion of the trachea: a 17-year experience in a single institute. Asian J Surg 32: 102\u2013108.","DOI":"10.1016\/S1015-9584(09)60019-1"},{"key":"295","doi-asserted-by":"crossref","unstructured":"296 Moritani S (2015) Surgical management of cricotracheal invasion by PTC. Ann Surg Oncol 22: 4002\u20134007.","DOI":"10.1245\/s10434-015-4492-5"},{"key":"296","doi-asserted-by":"crossref","unstructured":"297 McCarty TM, Kuhn JA, Williams WL Jr, Ellenhorn JD, O\u2019Brien JC, et al. (1997) Surgical management of thyroid cancer invading the airway. Ann Surg Oncol 4: 403\u2013408.","DOI":"10.1007\/BF02305553"},{"key":"297","doi-asserted-by":"crossref","unstructured":"298 Tsukahara K, Sugitani I, Kawabata K (2009) Surgical management of tracheal shaving for PTC with tracheal invasion. Acta Otolaryngol 129: 1498\u20131502.","DOI":"10.3109\/00016480902725239"},{"key":"298","doi-asserted-by":"crossref","unstructured":"299 Peng A, Li Y, Yang X, Xiao Z, Tang Q, et al. (2015) A review of the management and prognosis of thyroid carcinoma with tracheal invasion. Eur Arch Otorhinolaryngol 272: 1833\u20131843.","DOI":"10.1007\/s00405-014-3144-x"},{"key":"299","doi-asserted-by":"crossref","unstructured":"300 Kim H, Jung HJ, Lee SY, Kwon TK, Kim KH, et al. (2016) Prognostic factors of locally invasive well-differentiated thyroid carcinoma involving the trachea. Eur Arch Otorhinolaryngol 273: 1919\u20131926.","DOI":"10.1007\/s00405-015-3724-4"},{"key":"300","doi-asserted-by":"crossref","unstructured":"301 Czaja JM, McCaffrey TV (1997) The surgical management of laryngotracheal invasion by well-differentiated PTC. Arch Otolaryngol Head Neck Surg 123: 484\u2013490.","DOI":"10.1001\/archotol.1997.01900050030003"},{"key":"301","doi-asserted-by":"crossref","unstructured":"302 Park CS, Suh KW, Min JS (1993) Cartilage-shaving procedure for the control of tracheal cartilage invasion by thyroid carcinoma. Head Neck 15: 289\u2013291.","DOI":"10.1002\/hed.2880150403"},{"key":"302","doi-asserted-by":"crossref","unstructured":"303 Tsai YF, Tseng YL, Wu MH, Hung CJ, Lai WW, et al. (2005) Aggressive resection of the airway invaded by thyroid carcinoma. Br J Surg 92: 1382\u20131387.","DOI":"10.1002\/bjs.5124"},{"key":"303","doi-asserted-by":"crossref","unstructured":"304 Ozaki O, Sugino K, Mimura T, Ito K (1995) Surgery for patients with thyroid carcinoma invading the trachea: circumferential sleeve resection followed by end-to-end anastomosis. Surgery 117: 268\u2013271.","DOI":"10.1016\/S0039-6060(05)80200-4"},{"key":"304","doi-asserted-by":"crossref","unstructured":"305 Shin DH, Mark EJ, Suen HC, Grillo HC (1993) Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection. Hum Pathol 24: 866\u2013870.","DOI":"10.1016\/0046-8177(93)90136-5"},{"key":"305","doi-asserted-by":"crossref","unstructured":"306 Piazza C, Lancini D, Tomasoni M, D\u2019Cruz A, Hartl DM, et al. (2021) Tracheal and cricotracheal resection with end-to-end anastomosis for locally advanced thyroid cancer: a systematic review of the literature on 656 patients. Front Endocrinol (Lausanne) 12: 779999.","DOI":"10.3389\/fendo.2021.779999"},{"key":"306","doi-asserted-by":"publisher","unstructured":"307 Allen M, Spillinger A, Arianpour K, Johnson J, Johnson AP, et al. (2021) Tracheal resection in the management of thyroid cancer: an evidence-based approach. Laryngoscope 131: 932\u2013946.","DOI":"10.1002\/lary.29112"},{"key":"307","doi-asserted-by":"crossref","unstructured":"308 Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, et al. (2014) Airtight tracheocutaneostomy after window resection of the trachea for invasive PTC: experience of 109 cases. World J Surg 38: 660\u2013666.","DOI":"10.1007\/s00268-013-2197-0"},{"key":"308","doi-asserted-by":"publisher","unstructured":"309 Ebihara M, Kishimoto S, Hayashi R, Miyazaki M, Shinozaki T, et al. (2011) Window resection of the trachea and secondary reconstruction for invasion by differentiated thyroid carcinoma. Auris Nasus Larynx 38: 271\u2013275.","DOI":"10.1016\/j.anl.2010.09.003"},{"key":"309","doi-asserted-by":"crossref","unstructured":"310 Moritani S (2017) Window resection for intraluminal cricotracheal invasion by PTC. World J Surg 41: 1812\u20131819.","DOI":"10.1007\/s00268-017-3927-5"},{"key":"310","doi-asserted-by":"crossref","unstructured":"311 Piazza C, Del Bon F, Barbieri D, Grazioli P, Paderno A, et al. (2016) Tracheal and crico-tracheal resection and anastomosis for malignancies involving the thyroid gland and the airway. Ann Otol Rhinol Laryngol 125: 97\u2013104.","DOI":"10.1177\/0003489415599000"},{"key":"311","doi-asserted-by":"crossref","unstructured":"312 Gaissert HA, Honings J, Grillo HC, Donahue DM, Wain JC, et al. (2007) Segmental laryngotracheal and tracheal resection for invasive thyroid carcinoma. Ann Thorac Surg 83: 1952\u20131959.","DOI":"10.1016\/j.athoracsur.2007.01.056"},{"key":"312","doi-asserted-by":"crossref","unstructured":"313 McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF (1986) Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61: 978\u2013996.","DOI":"10.1016\/S0025-6196(12)62641-X"},{"key":"313","doi-asserted-by":"crossref","unstructured":"314 Su SY, Milas ZL, Bhatt N, Roberts D, Clayman GL (2016) Well-differentiated thyroid cancer with aerodigestive tract invasion: long-term control and functional outcomes. Head Neck 38: 72\u201378.","DOI":"10.1002\/hed.23851"},{"key":"314","doi-asserted-by":"crossref","unstructured":"315 Shadmehr MB, Farzanegan R, Zangi M, Mohammadzadeh A, Sheikhy K, et al. (2012) Thyroid cancers with laryngotracheal invasion. Eur J Cardiothorac Surg 41: 635\u2013640.","DOI":"10.1093\/ejcts\/ezr131"},{"key":"315","doi-asserted-by":"publisher","unstructured":"316 McCaffrey JC (2006) Aerodigestive tract invasion by well differentiated thyroid carcinoma : diagnosis, management, prognosis, and biology. Laryngoscope 116: 1\u201311.","DOI":"10.1097\/01.MLG.0000200428.26975.86"},{"key":"316","doi-asserted-by":"crossref","unstructured":"317 McCaffrey TV, Bergstralh EJ, Hay ID (1994) Locally invasive PTC: 1940\u20131990. Head Neck 16: 165\u2013172.","DOI":"10.1002\/hed.2880160211"},{"key":"317","doi-asserted-by":"publisher","unstructured":"318 Giovanni A, Guelfucci B, Gras R, Yu P, Zanaret M (2001) Partial frontolateral laryngectomy with epiglottic reconstruction for management of early-stage glottic carcinoma. Laryngoscope 111: 663\u2013668.","DOI":"10.1097\/00005537-200104000-00020"},{"key":"318","doi-asserted-by":"crossref","unstructured":"319 Biller HF, Ogura JH, Pratt LL (1971) Hemilaryngectomy for T2 glottic cancers. Arch Otolaryngol 93: 238\u2013243.","DOI":"10.1001\/archotol.1971.00770060376003"},{"key":"319","doi-asserted-by":"crossref","unstructured":"320 Price DL, Wong RJ, Randolph GW (2008) Invasive thyroid cancer: management of the trachea and esophagus. Otolaryngol Clin North Am 41: 1155\u20131168, ix\u2013x.","DOI":"10.1016\/j.otc.2008.08.002"},{"key":"320","doi-asserted-by":"crossref","unstructured":"321 Snyderman CH, D\u2019Amico F (1992) Outcome of carotid artery resection for neoplastic disease: a meta-analysis. Am J Otolaryngol 13: 373\u2013380.","DOI":"10.1016\/0196-0709(92)90079-9"},{"key":"321","doi-asserted-by":"publisher","unstructured":"322 Ozer E, Agrawal A, Ozer HG, Schuller DE (2008) The impact of surgery in the management of the head and neck carcinoma involving the carotid artery. Laryngoscope 118: 1771\u20131774.","DOI":"10.1097\/MLG.0b013e31817f6dc7"},{"key":"322","doi-asserted-by":"crossref","unstructured":"323 Yu Q, Wang P, Shi H, Luo J (2003) Carotid artery and jugular vein invasion of oral-maxillofacial and neck malignant tumors: diagnostic value of computed tomography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96: 368\u2013372.","DOI":"10.1016\/S1079-2104(03)00366-4"},{"key":"323","doi-asserted-by":"publisher","unstructured":"324 Yousem DM, Hatabu H, Hurst RW, Seigerman HM, Montone KT, et al. (1995) Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology 195: 715\u2013720.","DOI":"10.1148\/radiology.195.3.7754000"},{"key":"324","doi-asserted-by":"crossref","unstructured":"325 Moritani S (2019) Appropriateness of subadventitial resection for invasion of the carotid artery by PTC. World J Surg 43: 519\u2013526.","DOI":"10.1007\/s00268-018-4787-3"},{"key":"325","doi-asserted-by":"crossref","unstructured":"326 Eisele DW, Richmon JD (2013) Contemporary evaluation and management of parapharyngeal space neoplasms. J Laryngol Otol 127: 550\u2013555.","DOI":"10.1017\/S0022215113000686"},{"key":"326","unstructured":"327 Rouvi\u00e8re H (1967) Anatomie humaine, et topograhique (10th). Masson et Cie, Paris, France (In French)."},{"key":"327","doi-asserted-by":"publisher","unstructured":"328 McCormack KR, Sheline GE (1970) Retropharyngeal spread of carcinoma of the thyroid. Cancer 26: 1366\u20131369.","DOI":"10.1002\/1097-0142(197012)26:6<1366::AID-CNCR2820260627>3.0.CO;2-V"},{"key":"328","doi-asserted-by":"crossref","unstructured":"329 Moritani S (2016) Parapharyngeal metastasis of PTC. World J Surg 40: 350\u2013355.","DOI":"10.1007\/s00268-015-3321-0"},{"key":"329","unstructured":"330 Chouke KS, Whitehead RW, Parker AE (1952) Is there a closed lymphatic system connecting the thyroid and thymus gland? Surg Gynecol Obstet 54: 865\u2013871."},{"key":"330","doi-asserted-by":"crossref","unstructured":"331 Zhang TT, Qu N, Hu JQ, Shi RL, Wen D, et al. (2017) Mediastinal lymph node metastases in thyroid cancer: characteristics, predictive factors, and prognosis. Int J Endocrinol 2017: 1868165.","DOI":"10.1155\/2017\/1868165"},{"key":"331","doi-asserted-by":"crossref","unstructured":"332 Woo JH, Park KN, Lee JY, Lee SW (2016) Predictive factors of superior mediastinal nodal metastasis from PTC\u2014A prospective observational study. PLoS One 11: e0148420.","DOI":"10.1371\/journal.pone.0148420"},{"key":"332","doi-asserted-by":"crossref","unstructured":"333 Ito Y, Miyauchi A (2007) Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks. World J Surg 31: 905\u2013915.","DOI":"10.1007\/s00268-006-0722-0"},{"key":"333","doi-asserted-by":"crossref","unstructured":"334 Moritani S, Takenobu M, Yasunaga M, Kawamoto K, Fujii T, et al. (2022) Surgical indications for upper mediastinal dissection by sternotomy in patients with PTC. Endocr J 69: 1245\u20131251.","DOI":"10.1507\/endocrj.EJ22-0033"},{"key":"334","doi-asserted-by":"crossref","unstructured":"335 Ramadan S, Ugas MA, Berwick RJ, Notay M, Cho H, et al. (2012) Spinal metastasis in thyroid cancer. Head Neck Oncol 4: 39.","DOI":"10.1186\/1758-3284-4-39"},{"key":"335","doi-asserted-by":"crossref","unstructured":"336 Planty-Bonjour A, Dubory A, Terrier LM, Taibi T, Cook AR, et al. (2022) Spinal metastases from thyroid cancer: some prognostic factors. Eur J Surg Oncol 48: 292\u2013298.","DOI":"10.1016\/j.ejso.2021.09.001"},{"key":"336","doi-asserted-by":"crossref","unstructured":"337 Kushchayeva YS, Kushchayev SV, Carroll NM, Felger EA, Links TP, et al. (2014) Spinal metastases due to thyroid carcinoma: an analysis of 202 patients. Thyroid 24: 1488\u20131500.","DOI":"10.1089\/thy.2013.0633"},{"key":"337","doi-asserted-by":"publisher","unstructured":"338 Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, et al. (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366: 643\u2013648.","DOI":"10.1016\/S0140-6736(05)66954-1"},{"key":"338","doi-asserted-by":"crossref","unstructured":"339 Nooh A, Goulding K, Isler MH, Mottard S, Arteau A, et al. (2018) Early improvement in pain and functional outcome but not quality of life after surgery for metastatic long bone disease. Clin Orthop Relat Res 476: 535\u2013545.","DOI":"10.1007\/s11999.0000000000000065"},{"key":"339","doi-asserted-by":"crossref","unstructured":"340 Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, et al. (2018) Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol 126: 547\u2013557.","DOI":"10.1016\/j.radonc.2018.01.003"},{"key":"340","doi-asserted-by":"crossref","unstructured":"341 Handy JR, Bremner RM, Crocenzi TS, Detterbeck FC, Fernando HC, et al. (2019) Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg 107: 631\u2013649.","DOI":"10.1016\/j.athoracsur.2018.10.028"},{"key":"341","doi-asserted-by":"crossref","unstructured":"342 Talaat OM, Ali IM, Abolyazid SM, Abdelmaksoud B, Nasr IM (2020) Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases. Nucl Med Commun 41: 327\u2013335.","DOI":"10.1097\/MNM.0000000000001151"},{"key":"342","doi-asserted-by":"crossref","unstructured":"343 Qiu ZL, Song HJ, Xu YH, Luo QY (2011) Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab 96: 3078\u20133086.","DOI":"10.1210\/jc.2011-0093"},{"key":"343","doi-asserted-by":"crossref","unstructured":"344 Orita Y, Sugitani I, Matsuura M, Ushijima M, Tsukahara K, et al. (2010) Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery 147: 424\u2013431.","DOI":"10.1016\/j.surg.2009.10.009"},{"key":"344","doi-asserted-by":"crossref","unstructured":"345 Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, et al. (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86: 1568\u20131573.","DOI":"10.1210\/jcem.86.4.7390"},{"key":"345","doi-asserted-by":"crossref","unstructured":"346 Jannin A, Lamartina L, Moutarde C, Djennaoui M, Lion G, et al. (2022) Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival. Eur J Nucl Med Mol Imaging 49: 2401\u20132413.","DOI":"10.1007\/s00259-022-05697-w"},{"key":"346","doi-asserted-by":"crossref","unstructured":"347 Wu D, Gomes Lima CJ, Moreau SL, Kulkarni K, Zeymo A, et al. (2019) Improved survival after multimodal approach with (131)I treatment in patients with bone metastases secondary to differentiated thyroid cancer. Thyroid 29: 971\u2013978.","DOI":"10.1089\/thy.2018.0582"},{"key":"347","doi-asserted-by":"crossref","unstructured":"348 Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, et al. (2018) Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Endocrine 59: 90\u2013101.","DOI":"10.1007\/s12020-017-1455-6"},{"key":"348","doi-asserted-by":"crossref","unstructured":"349 Nakayama R, Horiuchi K, Susa M, Watanabe I, Watanabe K, et al. (2014) Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC): a retrospective study of 40 cases. Jpn J Clin Oncol 44: 918\u2013925.","DOI":"10.1093\/jjco\/hyu099"},{"key":"349","doi-asserted-by":"crossref","unstructured":"350 Moneke I, Kaifi JT, Kloeser R, Samson P, Haager B, et al. (2018) Pulmonary metastasectomy for thyroid cancer as salvage therapy for radioactive iodine-refractory metastases. Eur J Cardiothorac Surg 53: 625\u2013630.","DOI":"10.1093\/ejcts\/ezx367"},{"key":"350","doi-asserted-by":"crossref","unstructured":"351 Fragnaud H, Mattei JC, Le Nail LR, Nguyen MV, Schubert T, et al. (2022) Mid and long-term overall survival after carcinologic resections of thyroid cancer bone metastases. Front Surg 9: 965951.","DOI":"10.3389\/fsurg.2022.965951"},{"key":"351","doi-asserted-by":"crossref","unstructured":"352 Bernstein MB, Chang EL, Amini B, Pan H, Cabanillas M, et al. (2016) Spine stereotactic radiosurgery for patients with metastatic thyroid cancer: secondary analysis of phase I\/II trials. Thyroid 26: 1269\u20131275.","DOI":"10.1089\/thy.2016.0046"},{"key":"352","doi-asserted-by":"crossref","unstructured":"353 Jiang L, Ouyang H, Liu X, Wei F, Wu F, et al. (2014) Surgical treatment of 21 patients with spinal metastases of differentiated thyroid cancer. Chin Med J (Engl) 127: 4092\u20134096.","DOI":"10.3760\/cma.j.issn.0366-6999.20141625"},{"key":"353","doi-asserted-by":"crossref","unstructured":"354 Demura S, Kawahara N, Murakami H, Abdel-Wanis ME, Kato S, et al. (2011) Total en bloc spondylectomy for spinal metastases in thyroid carcinoma. J Neurosurg Spine 14: 172\u2013176.","DOI":"10.3171\/2010.9.SPINE09878"},{"key":"354","doi-asserted-by":"crossref","unstructured":"355 Kato S, Murakami H, Demura S, Fujimaki Y, Yoshioka K, et al. (2016) The impact of complete surgical resection of spinal metastases on the survival of patients with thyroid cancer. Cancer Med 5: 2343\u20132349.","DOI":"10.1002\/cam4.823"},{"key":"355","doi-asserted-by":"crossref","first-page":"E1741","DOI":"10.1002\/lary.29321","volume":"131","author":"LX Yin","year":"2021","unstructured":"356 Yin LX, Puccinelli CL, Van Abel K, Kasperbauer JL, Price DL, et al. (2021) Prognostic factors in patients with differentiated thyroid cancers metastatic to the cervical spine. Laryngoscope 131: E1741\u2013E1747.","journal-title":"The Laryngoscope","ISSN":"https:\/\/id.crossref.org\/issn\/0023-852X","issn-type":"print"},{"key":"356","doi-asserted-by":"crossref","unstructured":"357 Sellin JN, Suki D, Harsh V, Elder BD, Fahim DK, et al. (2015) Factors affecting survival in 43 consecutive patients after surgery for spinal metastases from thyroid carcinoma. J Neurosurg Spine 23: 419\u2013428.","DOI":"10.3171\/2015.1.SPINE14431"},{"key":"357","doi-asserted-by":"crossref","unstructured":"358 Zhang D, Gong H, Shen M, Wang D, Jiao J, et al. (2019) Surgical management and factors affecting the prognosis for patients with thyroid cancer spinal metastases: a retrospective analysis of 52 consecutive patients from a single center. World Neurosurg 129: e330\u2013e336.","DOI":"10.1016\/j.wneu.2019.05.143"},{"key":"358","doi-asserted-by":"crossref","unstructured":"359 Farooki A, Leung V, Tala H, Tuttle RM (2012) Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab 97: 2433\u20132439.","DOI":"10.1210\/jc.2012-1169"},{"key":"359","doi-asserted-by":"crossref","unstructured":"360 Orita Y, Sugitani I, Takao S, Toda K, Manabe J, et al. (2015) Prospective evaluation of zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. Ann Surg Oncol 22: 4008\u20134013.","DOI":"10.1245\/s10434-015-4497-0"},{"key":"360","doi-asserted-by":"crossref","unstructured":"361 Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, et al. (2003) Zoledronic acid <i>versus<\/i> placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 3150\u20133157.","DOI":"10.1200\/JCO.2003.04.105"},{"key":"361","doi-asserted-by":"crossref","unstructured":"362 Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, et al. (2011) Randomized, double-blind study of denosumab <i>versus<\/i> zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125\u20131132.","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"362","doi-asserted-by":"crossref","unstructured":"363 Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, et al. (2012) Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab <i>versus<\/i> zoledronic acid. Ann Oncol 23: 3045\u20133051.","DOI":"10.1093\/annonc\/mds175"},{"key":"363","doi-asserted-by":"crossref","unstructured":"364 Chen F, Pu F (2016) Safety of denosumab <i>versus<\/i> zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat 39: 453\u2013459.","DOI":"10.1159\/000447372"},{"key":"364","doi-asserted-by":"crossref","unstructured":"365 Chen J, Zhou L, Liu X, Wen X, Li H, et al. (2021) Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis. Int J Clin Pharm 43: 2\u201310.","DOI":"10.1007\/s11096-020-01105-1"},{"key":"365","doi-asserted-by":"crossref","unstructured":"366 Jiang L, Cui X, Ma H, Tang X (2021) Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials. J Orthop Surg Res 16: 400.","DOI":"10.1186\/s13018-021-02554-8"},{"key":"366","doi-asserted-by":"crossref","unstructured":"367 Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, et al. (2019) Brain metastases from differentiated thyroid carcinoma: prevalence, current therapies, and outcomes. J Endocr Soc 3: 359\u2013371.","DOI":"10.1210\/js.2018-00241"},{"key":"367","doi-asserted-by":"crossref","unstructured":"368 Saito F, Uruno T, Shibuya H, Kitagawa W, Nagahama M, et al. (2016) Prognosis after brain metastasis from differentiated thyroid carcinoma. World J Surg 40: 574\u2013581.","DOI":"10.1007\/s00268-016-3405-5"},{"key":"368","doi-asserted-by":"crossref","unstructured":"369 Choi J, Kim JW, Keum YS, Lee IJ (2016) The largest known survival analysis of patients with brain metastasis from thyroid cancer based on prognostic groups. PLoS One 11: e0154739.","DOI":"10.1371\/journal.pone.0154739"},{"key":"369","doi-asserted-by":"crossref","unstructured":"370 Osborne JR, Kondraciuk JD, Rice SL, Zhou X, Knezevic A, et al. (2019) Thyroid cancer brain metastasis: survival and genomic characteristics of a large tertiary care cohort. Clin Nucl Med 44: 544\u2013549.","DOI":"10.1097\/RLU.0000000000002618"},{"key":"370","doi-asserted-by":"crossref","unstructured":"371 Hong YW, Lin JD, Yu MC, Hsu CC, Lin YS (2018) Outcomes and prognostic factors in thyroid cancer patients with cranial metastases: a retrospective cohort study of 4,683 patients. Int J Surg 55: 182\u2013187.","DOI":"10.1016\/j.ijsu.2018.06.001"},{"key":"371","doi-asserted-by":"publisher","unstructured":"372 McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, et al. (2003) Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer 98: 356\u2013362.","DOI":"10.1002\/cncr.11488"},{"key":"372","doi-asserted-by":"crossref","unstructured":"373 Chiu AC, Delpassand ES, Sherman SI (1997) Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82: 3637\u20133642.","DOI":"10.1210\/jcem.82.11.4386"},{"key":"373","doi-asserted-by":"crossref","unstructured":"374 Wu T, Jiao Z, Li Y, Peng J, Yao F, et al. (2021) Brain metastases from differentiated thyroid carcinoma: a retrospective study of 22 patients. Front Endocrinol (Lausanne) 12: 730025.","DOI":"10.3389\/fendo.2021.730025"},{"key":"374","doi-asserted-by":"publisher","unstructured":"375 Henriques de Figueiredo B, Godbert Y, Soubeyran I, Carrat X, Lagarde P, et al. (2014) Brain metastases from thyroid carcinoma: a retrospective study of 21 patients. Thyroid 24: 270\u2013276.","DOI":"10.1089\/thy.2013.0061"},{"key":"375","doi-asserted-by":"crossref","unstructured":"376 Bernad DM, Sperduto PW, Souhami L, Jensen AW, Roberge D (2010) Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers. J Neurooncol 98: 249\u2013252.","DOI":"10.1007\/s11060-010-0175-z"},{"key":"376","doi-asserted-by":"crossref","unstructured":"377 Kim IY, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD (2009) Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer. J Neurooncol 93: 355\u2013359.","DOI":"10.1007\/s11060-008-9783-2"},{"key":"377","doi-asserted-by":"crossref","unstructured":"378 Bunevicius A, Fribance S, Pikis S, Lee JYK, Buch LY, et al. (2021) Stereotactic radiosurgery for differentiated thyroid cancer brain metastases: an international, multicenter study. Thyroid 31: 1244\u20131252.","DOI":"10.1089\/thy.2020.0947"},{"key":"378","doi-asserted-by":"crossref","unstructured":"379 Blomain E, Berta S, Hug N, Giao D, Meola A, et al. (2022) Radiotherapy for brain metastases from thyroid cancer: an institutional and national retrospective cohort study. Thyroid 32: 781\u2013788.","DOI":"10.1089\/thy.2021.0628"},{"key":"379","doi-asserted-by":"crossref","unstructured":"380 Dziggel L, Gebauer N, Bartscht T, Schild SE, Rades D (2018) Performance status and number of metastatic extra-cerebral sites predict survival after radiotherapy of brain metastases from thyroid cancer. Anticancer Res 38: 2391\u20132394.","DOI":"10.21873\/anticanres.12488"},{"key":"380","doi-asserted-by":"crossref","unstructured":"381 Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70: 510\u2013514.","DOI":"10.1016\/j.ijrobp.2007.06.074"},{"key":"381","doi-asserted-by":"crossref","unstructured":"382 Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, et al. (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494\u2013500.","DOI":"10.1056\/NEJM199002223220802"},{"key":"382","doi-asserted-by":"crossref","unstructured":"383 Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, et al. (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33: 583\u2013590.","DOI":"10.1002\/ana.410330605"},{"key":"383","doi-asserted-by":"publisher","unstructured":"384 Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, et al. (2006) Stereotactic radiosurgery plus whole-brain radiation therapy <i>vs.<\/i> stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295: 2483\u20132491.","DOI":"10.1001\/jama.295.21.2483"},{"key":"384","doi-asserted-by":"crossref","unstructured":"385 Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, et al. (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15: 387\u2013395.","DOI":"10.1016\/S1470-2045(14)70061-0"},{"key":"385","doi-asserted-by":"crossref","unstructured":"386 Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, et al. (2016) Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 388: 2004\u20132014.","DOI":"10.1016\/S0140-6736(16)30825-X"},{"key":"386","doi-asserted-by":"crossref","unstructured":"387 Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, et al. (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22: 157\u2013165.","DOI":"10.1200\/JCO.2004.05.128"},{"key":"387","doi-asserted-by":"publisher","unstructured":"388 Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, et al. (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280: 1485\u20131489.","DOI":"10.1001\/jama.280.17.1485"},{"key":"388","doi-asserted-by":"crossref","unstructured":"389 Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, et al. (2015) Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91: 710\u2013717.","DOI":"10.1016\/j.ijrobp.2014.10.024"},{"key":"389","doi-asserted-by":"crossref","unstructured":"390 Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, et al. (2016) Effect of radiosurgery alone <i>vs.<\/i> radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316: 401\u2013409.","DOI":"10.1001\/jama.2016.9839"},{"key":"390","doi-asserted-by":"crossref","unstructured":"391 Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711\u2013723.","DOI":"10.1056\/NEJMx100063"},{"key":"391","doi-asserted-by":"crossref","unstructured":"392 Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, et al. (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357: 409\u2013413.","DOI":"10.1126\/science.aan6733"},{"key":"392","doi-asserted-by":"crossref","unstructured":"393 Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, et al. (2022) Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 33: 929\u2013938.","DOI":"10.1016\/j.annonc.2022.05.519"},{"key":"393","doi-asserted-by":"crossref","unstructured":"394 Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, et al. (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21: 1353\u20131365.","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"394","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","volume":"19","author":"JM Mehnert","year":"2019","unstructured":"395 Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, et al. (2019) Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 19: 196.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"395","doi-asserted-by":"crossref","unstructured":"396 Oh DY, Algazi A, Capdevila J, Longo F, Miller W Jr, et al. (2023) Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer 129: 1195\u20131204.","DOI":"10.1002\/cncr.34657"},{"key":"396","doi-asserted-by":"crossref","unstructured":"397 Rocha ML, Schmid KW, Czapiewski P (2021) The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma\u2014systematic review and discussion of current therapeutic options. Contemp Oncol (Pozn) 25: 213\u2013223.","DOI":"10.5114\/wo.2021.110052"},{"key":"397","doi-asserted-by":"crossref","unstructured":"398 Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, et al. (2020) PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 38: 2620\u20132627.","DOI":"10.1200\/JCO.19.02727"},{"key":"398","doi-asserted-by":"crossref","unstructured":"399 Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, et al. (2021) Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol 26: 233\u2013283.","DOI":"10.1007\/s10147-020-01831-6"},{"key":"399","doi-asserted-by":"crossref","unstructured":"400 Sunami K, Naito Y, Komine K, Amano T, Ennishi D, et al. (2022) Chronological improvement in precision oncology implementation in Japan. Cancer Sci 113: 3995\u20134000.","DOI":"10.1111\/cas.15517"},{"key":"400","doi-asserted-by":"crossref","unstructured":"401 Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, et al. (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383: 825\u2013835.","DOI":"10.1056\/NEJMoa2005651"},{"key":"401","doi-asserted-by":"crossref","unstructured":"402 Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, et al. (2024) A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. Thyroid 34: 467\u2013476.","DOI":"10.1089\/thy.2023.0547"},{"key":"402","doi-asserted-by":"crossref","unstructured":"403 Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, et al. (2022) Dabrafenib <i>versus<\/i> dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 32: 1184\u20131192.","DOI":"10.1089\/thy.2022.0115"},{"key":"403","doi-asserted-by":"crossref","unstructured":"404 Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, et al. (2022) Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 33: 406\u2013415.","DOI":"10.1016\/j.annonc.2021.12.014"},{"key":"404","doi-asserted-by":"crossref","unstructured":"405 Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, et al. (2016) Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17: 1272\u20131282.","DOI":"10.1016\/S1470-2045(16)30166-8"},{"key":"405","doi-asserted-by":"crossref","unstructured":"406 Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, et al. (2018) Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 36: 7\u201313.","DOI":"10.1200\/JCO.2017.73.6785"},{"key":"406","doi-asserted-by":"crossref","unstructured":"407 Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, et al. (2023) Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 29: 1103\u20131112.","DOI":"10.1038\/s41591-023-02321-8"},{"key":"407","doi-asserted-by":"crossref","unstructured":"408 Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, et al. (2015) BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25: 71\u201377.","DOI":"10.1089\/thy.2014.0123"},{"key":"408","doi-asserted-by":"crossref","unstructured":"409 Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, et al. (2021) Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol 9: 491\u2013501.","DOI":"10.1016\/S2213-8587(21)00120-0"},{"key":"409","doi-asserted-by":"crossref","unstructured":"410 Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, et al. (2023) Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 389: 1851\u20131861.","DOI":"10.1056\/NEJMoa2309719"},{"key":"410","doi-asserted-by":"crossref","unstructured":"411 Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, et al. (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 21: 271\u2013282.","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"411","doi-asserted-by":"crossref","unstructured":"412 Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, et al. (2022) Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186: 631\u2013643.","DOI":"10.1530\/EJE-21-1259"},{"key":"412","doi-asserted-by":"publisher","unstructured":"413 Cancer Genome Atlas Research Network  (2014) Integrated genomic characterization of PTC. Cell 159: 676\u2013690.","DOI":"10.1016\/j.cell.2014.09.050"},{"key":"413","doi-asserted-by":"crossref","unstructured":"414 Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C (2014) The landscape of kinase fusions in cancer. Nat Commun 5: 4846.","DOI":"10.1038\/ncomms5846"},{"key":"414","doi-asserted-by":"crossref","unstructured":"415 Gouda MA, Nelson BE, Buschhorn L, Wahida A, Subbiah V (2023) Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications. Clin Cancer Res 29: 2753\u20132760.","DOI":"10.1158\/1078-0432.CCR-23-0090"},{"key":"415","doi-asserted-by":"crossref","unstructured":"416 Vanden Borre P, Schrock AB, Anderson PM, Morris JC 3rd, Heilmann AM, et al. (2017) Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions. Oncologist 22: 255\u2013263.","DOI":"10.1634\/theoncologist.2016-0279"},{"key":"416","doi-asserted-by":"crossref","unstructured":"417 O\u2019Haire S, Franchini F, Kang YJ, Steinberg J, Canfell K, et al. (2023) Systematic review of NTRK 1\/2\/3 fusion prevalence pan-cancer and across solid tumours. Sci Rep 13: 4116.","DOI":"10.1038\/s41598-023-31055-3"},{"key":"417","doi-asserted-by":"crossref","unstructured":"418 Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, et al. (2021) Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol 5: 69.","DOI":"10.1038\/s41698-021-00206-y"},{"key":"418","doi-asserted-by":"crossref","unstructured":"419 Ricarte-Filho JC, Halada S, O\u2019Neill A, Casado-Medrano V, Laetsch TW, et al. (2022) The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer. Cancer Genet 262\u2013263: 57\u201363.","DOI":"10.1016\/j.cancergen.2022.01.002"},{"key":"419","doi-asserted-by":"crossref","unstructured":"420 Shao C, Li G, Huang L, Pruitt S, Castellanos E, et al. (2020) Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw Open 3: e2025109.","DOI":"10.1001\/jamanetworkopen.2020.25109"},{"key":"420","doi-asserted-by":"crossref","unstructured":"421 Genutis LK, Tomsic J, Bundschuh RA, Brock PL, Williams MD, et al. (2019) Microsatellite instability occurs in a subset of follicular thyroid cancers. Thyroid 29: 523\u2013529.","DOI":"10.1089\/thy.2018.0655"},{"key":"421","doi-asserted-by":"crossref","unstructured":"422 Hause RJ, Pritchard CC, Shendure J, Salipante SJ (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22: 1342\u20131350.","DOI":"10.1038\/nm.4191"},{"key":"422","doi-asserted-by":"crossref","unstructured":"423 Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, et al. (2014) Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99: 2086\u20132094.","DOI":"10.1210\/jc.2013-3588"},{"key":"423","doi-asserted-by":"publisher","unstructured":"424 Oh HS, Shin DY, Kim M, Park SY, Kim TH, et al. (2019) Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a Korean multicenter study. Thyroid 29: 1804\u20131810.","DOI":"10.1089\/thy.2019.0246"},{"key":"424","doi-asserted-by":"crossref","unstructured":"425 Kish JK, Chatterjee D, Wan Y, Yu HT, Liassou D, et al. (2020) Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer: a real-world study of clinical effectiveness in the United States. Adv Ther 37: 2841\u20132852.","DOI":"10.1007\/s12325-020-01362-6"},{"key":"425","doi-asserted-by":"crossref","unstructured":"426 Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, et al. (2018) Lenvatinib in advanced radioiodine-refractory thyroid cancer\u2014a retrospective analysis of the Swiss lenvatinib named patient program. J Cancer 9: 250\u2013255.","DOI":"10.7150\/jca.22318"},{"key":"426","doi-asserted-by":"crossref","unstructured":"427 Owonikoko TK, Chowdry RP, Chen Z, Kim S, Saba NF, et al. (2013) Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. Oncologist 18: 1262\u20131269.","DOI":"10.1634\/theoncologist.2013-0250"},{"key":"427","doi-asserted-by":"crossref","unstructured":"428 Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, et al. (2014) Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 170: 575\u2013582.","DOI":"10.1530\/EJE-13-0825"},{"key":"428","doi-asserted-by":"crossref","unstructured":"429 Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, et al. (2010) Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16: 5260\u20135268.","DOI":"10.1158\/1078-0432.CCR-10-0994"},{"key":"429","doi-asserted-by":"crossref","unstructured":"430 Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI (2014) A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24: 1508\u20131514.","DOI":"10.1089\/thy.2014.0125"},{"key":"430","doi-asserted-by":"publisher","unstructured":"431 Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, et al. (2015) A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121: 2749\u20132756.","DOI":"10.1002\/cncr.29395"},{"key":"431","doi-asserted-by":"crossref","unstructured":"432 Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, et al. (2017) Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial. J Clin Oncol 35: 3315\u20133321.","DOI":"10.1200\/JCO.2017.73.0226"},{"key":"432","doi-asserted-by":"crossref","unstructured":"433 Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, et al. (2015) Lenvatinib <i>versus<\/i> placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372: 621\u2013630.","DOI":"10.1056\/NEJMoa1406470"},{"key":"433","doi-asserted-by":"crossref","unstructured":"434 Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, et al. (2021) Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 22: 1126\u20131138.","DOI":"10.1016\/S1470-2045(21)00332-6"},{"key":"434","doi-asserted-by":"crossref","unstructured":"435 Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, et al. (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384: 319\u2013328.","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"435","doi-asserted-by":"crossref","unstructured":"436 Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, et al. (2018) Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib <i>versus<\/i> vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19: 1315\u20131327.","DOI":"10.1016\/S1470-2045(18)30497-2"},{"key":"436","doi-asserted-by":"crossref","unstructured":"437 Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, et al. (2018) Encorafenib plus binimetinib <i>versus<\/i> vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19: 603\u2013615.","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"437","doi-asserted-by":"crossref","unstructured":"438 Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, et al. (2023) Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer. J Clin Oncol 41: 3700\u20133711.","DOI":"10.1200\/JCO.23.00774"},{"key":"438","doi-asserted-by":"crossref","unstructured":"439 Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, et al. (2022) Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 28: 1302\u20131312.","DOI":"10.1158\/1078-0432.CCR-21-3597"},{"key":"439","doi-asserted-by":"crossref","unstructured":"440 Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, et al. (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378: 731\u2013739.","DOI":"10.1056\/NEJMoa1714448"},{"key":"440","doi-asserted-by":"crossref","unstructured":"441 Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, et al. (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 21: 531\u2013540.","DOI":"10.1016\/S1470-2045(19)30856-3"},{"key":"441","doi-asserted-by":"crossref","unstructured":"442 Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, et al. (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30: 134\u2013141.","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"442","doi-asserted-by":"crossref","unstructured":"443 Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, et al. (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31: 3639\u20133646.","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"443","doi-asserted-by":"crossref","unstructured":"444 Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, et al. (2022) LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naive RET-mutant medullary thyroid cancer. Future Oncol 18: 3143\u20133150.","DOI":"10.2217\/fon-2022-0657"},{"key":"444","doi-asserted-by":"crossref","unstructured":"445 Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, et al. (2017) Lenvatinib for anaplastic thyroid cancer. Front Oncol 7: 25.","DOI":"10.3389\/fonc.2017.00025"},{"key":"445","doi-asserted-by":"crossref","unstructured":"446 Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, et al. (2021) Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol 39: 2359\u20132366.","DOI":"10.1200\/JCO.20.03093"},{"key":"446","doi-asserted-by":"crossref","unstructured":"447 Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, et al. (2012) A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 97: 3179\u20133184.","DOI":"10.1210\/jc.2012-1520"},{"key":"447","doi-asserted-by":"crossref","unstructured":"448 Ravaud A, de la Fouchardiere C, Caron P, Doussau A, Do Cao C, et al. (2017) A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer 76: 110\u2013117.","DOI":"10.1016\/j.ejca.2017.01.029"},{"key":"448","doi-asserted-by":"publisher","unstructured":"449 Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, et al. (2017) Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 27: 1142\u20131148.","DOI":"10.1089\/thy.2016.0621"},{"key":"449","doi-asserted-by":"crossref","unstructured":"450 Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, et al. (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373: 726\u2013736.","DOI":"10.1056\/NEJMoa1502309"},{"key":"450","doi-asserted-by":"publisher","unstructured":"451 Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. (2015) Dabrafenib and trametinib <i>versus<\/i> dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386: 444\u2013451.","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"451","doi-asserted-by":"crossref","unstructured":"452 Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, et al. (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372: 30\u201339.","DOI":"10.1056\/NEJMoa1412690"},{"key":"452","doi-asserted-by":"crossref","unstructured":"453 Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, et al. (2016) Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17: 984\u2013993.","DOI":"10.1016\/S1470-2045(16)30146-2"},{"key":"453","doi-asserted-by":"crossref","unstructured":"454 Lee JS KJ, Ryu JS, Woo SH (2018) Effect of wound massage on neck discomfort and voice changes after thyroidectomy. Surgery 164: 965\u2013971.","DOI":"10.1016\/j.surg.2018.05.029"},{"key":"454","doi-asserted-by":"crossref","unstructured":"455 Rosenbaum MA, Haridas M, McHenry CR (2008) Life-threatening neck hematoma complicating thyroid and parathyroid surgery. Am J Surg 195: 339\u2013343; discussion 343.","DOI":"10.1016\/j.amjsurg.2007.12.008"},{"key":"455","doi-asserted-by":"crossref","unstructured":"456 Promberger R, Ott J, Kober F, Koppitsch C, Seemann R, et al. (2012) Risk factors for postoperative bleeding after thyroid surgery. Br J Surg 99: 373\u2013379.","DOI":"10.1002\/bjs.7824"},{"key":"456","doi-asserted-by":"crossref","unstructured":"457 Weiss A, Lee KC, Brumund KT, Chang DC, Bouvet M (2014) Risk factors for hematoma after thyroidectomy: results from the nationwide inpatient sample. Surgery 156: 399\u2013404.","DOI":"10.1016\/j.surg.2014.03.015"},{"key":"457","unstructured":"458 Chen E, Cai Y, Li Q, Cheng P, Ni C, et al. (2014) Risk factors target in patients with post-thyroidectomy bleeding. Int J Clin Exp Med 7: 1837\u20131844."},{"key":"458","doi-asserted-by":"crossref","unstructured":"459 Suzuki S, Yasunaga H, Matsui H, Fushimi K, Saito Y, et al. (2016) Factors associated with neck hematoma after thyroidectomy: a retrospective analysis using a Japanese inpatient database. Medicine (Baltimore) 95: e2812.","DOI":"10.1097\/MD.0000000000002812"},{"key":"459","doi-asserted-by":"crossref","unstructured":"460 Wojtczak B, Aporowicz M, Kaliszewski K, Bolanowski M (2018) Consequences of bleeding after thyroid surgery\u2014analysis of 7805 operations performed in a single center. Arch Med Sci 14: 329\u2013335.","DOI":"10.5114\/aoms.2016.63004"},{"key":"460","doi-asserted-by":"crossref","unstructured":"461 Edafe O, Cochrane E, Balasubramanian SP (2020) Reoperation for bleeding after thyroid and parathyroid surgery: incidence, risk factors, prevention, and management. World J Surg 44: 1156\u20131162.","DOI":"10.1007\/s00268-019-05322-2"},{"key":"461","first-page":"S1","volume":"121 Suppl 1","author":"GW Randolph","year":"2011","unstructured":"462 Randolph GW, Dralle H, Abdullah H, Barczynski M, Bellantone R, et al. (2011) Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope 121 Suppl 1: S1\u2013S16.","journal-title":"The Laryngoscope","ISSN":"https:\/\/id.crossref.org\/issn\/0023-852X","issn-type":"print"},{"key":"462","first-page":"S1","volume":"123 Suppl 4","author":"M Barczynski","year":"2013","unstructured":"463 Barczynski M, Randolph GW, Cernea CR, Dralle H, Dionigi G, et al. (2013) External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope 123 Suppl 4: S1\u2013S14.","journal-title":"The Laryngoscope","ISSN":"https:\/\/id.crossref.org\/issn\/0023-852X","issn-type":"print"},{"key":"463","doi-asserted-by":"crossref","unstructured":"464 Dralle H, Sekulla C, Haerting J, Timmermann W, Neumann HJ, et al. (2004) Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 136: 1310\u20131322.","DOI":"10.1016\/j.surg.2004.07.018"},{"key":"464","doi-asserted-by":"crossref","unstructured":"465 Malik R, Linos D (2016) Intraoperative neuromonitoring in thyroid surgery: a systematic review. World J Surg 40: 2051\u20132058.","DOI":"10.1007\/s00268-016-3594-y"},{"key":"465","doi-asserted-by":"crossref","unstructured":"466 Zheng S, Xu Z, Wei Y, Zeng M, He J (2013) Effect of intraoperative neuromonitoring on recurrent laryngeal nerve palsy rates after thyroid surgery\u2014a meta-analysis. J Formos Med Assoc 112: 463\u2013472.","DOI":"10.1016\/j.jfma.2012.03.003"},{"key":"466","doi-asserted-by":"crossref","unstructured":"467 Anuwong A, Lavazza M, Kim HY, Wu CW, Rausei S, et al. (2016) Recurrent laryngeal nerve management in thyroid surgery: consequences of routine visualization, application of intermittent, standardized and continuous nerve monitoring. Updates Surg 68: 331\u2013341.","DOI":"10.1007\/s13304-016-0393-9"},{"key":"467","doi-asserted-by":"crossref","unstructured":"468 Calo PG, Pisano G, Medas F, Pittau MR, Gordini L, et al. (2014) Identification alone <i>versus<\/i> intraoperative neuromonitoring of the recurrent laryngeal nerve during thyroid surgery: experience of 2034 consecutive patients. J Otolaryngol Head Neck Surg 43: 16.","DOI":"10.1186\/1916-0216-43-16"},{"key":"468","doi-asserted-by":"crossref","unstructured":"469 Barczynski M, Konturek A, Cichon S (2009) Randomized clinical trial of visualization <i>versus<\/i> neuromonitoring of recurrent laryngeal nerves during thyroidectomy. Br J Surg 96: 240\u2013246.","DOI":"10.1002\/bjs.6417"},{"key":"469","doi-asserted-by":"crossref","unstructured":"470 Barczynski M, Konturek A, Stopa M, Honowska A, Nowak W (2012) Randomized controlled trial of visualization <i>versus<\/i> neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy. World J Surg 36: 1340\u20131347.","DOI":"10.1007\/s00268-012-1547-7"},{"key":"470","doi-asserted-by":"crossref","unstructured":"471 Masuoka H, Miyauchi A, Higashiyama T, Yabuta T, Fukushima M, et al. (2015) Prospective randomized study on injury of the external branch of the superior laryngeal nerve during thyroidectomy comparing intraoperative nerve monitoring and a conventional technique. Head Neck 37: 1456\u20131460.","DOI":"10.1002\/hed.23778"},{"key":"471","doi-asserted-by":"crossref","unstructured":"472 Genther DJ KE, Noureldine SI, Tufano RP (2014) 24384927 Correlation of final evoked potential amplitudes on intraoperative electromyography of the recurrent laryngeal nerve with immediate postoperative vocal fold function after thyroid and parathyroid surgery. JAMA Otolaryngol Head Neck Surg 140: 124\u2013128.","DOI":"10.1001\/jamaoto.2013.6139"},{"key":"472","doi-asserted-by":"crossref","unstructured":"473 Melin M, Schwarz K, Pearson MD, Lammers BJ, Goretzki PE (2014) Postoperative vocal cord dysfunction despite normal intraoperative neuromonitoring: an unexpected complication with the risk of bilateral palsy. World J Surg 38: 2597\u20132602.","DOI":"10.1007\/s00268-014-2591-2"},{"key":"473","doi-asserted-by":"crossref","unstructured":"474 Tomoda C, Hirokawa Y, Uruno T, Takamura Y, Ito Y, et al. (2006) Sensitivity and specificity of intraoperative recurrent laryngeal nerve stimulation test for predicting vocal cord palsy after thyroid surgery. World J Surg 30: 1230\u20131233.","DOI":"10.1007\/s00268-005-0351-z"},{"key":"474","doi-asserted-by":"crossref","unstructured":"475 Sari S, Erbil Y, Sumer A, Agcaoglu O, Bayraktar A, et al. (2010) Evaluation of recurrent laryngeal nerve monitoring in thyroid surgery. Int J Surg 8: 474\u2013478.","DOI":"10.1016\/j.ijsu.2010.06.009"},{"key":"475","unstructured":"476 Sun H, Tian W, Jiang K, Chiang F, Wang P, et al. (2015) Clinical guidelines on intraoperative neuromonitoring during thyroid and parathyroid surgery. Ann Transl Med 3: 213."},{"key":"476","doi-asserted-by":"crossref","unstructured":"477 Dionigi G, Chiang FY, Dralle H, Boni L, Rausei S, et al. (2013) Safety of neural monitoring in thyroid surgery. Int J Surg 11 Suppl 1: S120\u2013S126.","DOI":"10.1016\/S1743-9191(13)60031-X"},{"key":"477","doi-asserted-by":"publisher","unstructured":"478 Friedrich C, Ulmer C, Rieber F, Kern E, Kohler A, et al. (2012) Safety analysis of vagal nerve stimulation for continuous nerve monitoring during thyroid surgery. Laryngoscope 122: 1979\u20131987.","DOI":"10.1002\/lary.23411"},{"key":"478","doi-asserted-by":"crossref","unstructured":"479 Barczynski M, Konturek A, Pragacz K, Papier A, Stopa M, et al. (2014) Intraoperative nerve monitoring can reduce prevalence of recurrent laryngeal nerve injury in thyroid reoperations: results of a retrospective cohort study. World J Surg 38: 599\u2013606.","DOI":"10.1007\/s00268-013-2260-x"},{"key":"479","doi-asserted-by":"crossref","unstructured":"480 Onoda N, Noda S, Tauchi Y, Asano Y, Kusunoki Y, et al. (2019) Continuous intraoperative neuromonitoring for thyroid cancer surgery: a prospective study. Laryngoscope Investig Otolaryngol 4: 455\u2013459.","DOI":"10.1002\/lio2.290"},{"key":"480","doi-asserted-by":"crossref","unstructured":"481 Kay-Rivest E, Mitmaker E, Payne RJ, Hier MP, Mlynarek AM, et al. (2015) Preoperative vocal cord paralysis and its association with malignant thyroid disease and other pathological features. J Otolaryngol Head Neck Surg 44: 35.","DOI":"10.1186\/s40463-015-0087-1"},{"key":"481","unstructured":"482 Franch-Arcas G, Gonzalez-Sanchez C, Aguilera-Molina YY, Rozo-Coronel O, Estevez-Alonso JS, et al. (2015) Is there a case for selective, rather than routine, preoperative laryngoscopy in thyroid surgery? Gland Surg 4: 8\u201318."},{"key":"482","doi-asserted-by":"crossref","unstructured":"483 Nam IC, Bae JS, Shim MR, Hwang YS, Kim MS, et al. (2012) The importance of preoperative laryngeal examination before thyroidectomy and the usefulness of a voice questionnaire in screening. World J Surg 36: 303\u2013309.","DOI":"10.1007\/s00268-011-1347-5"},{"key":"483","doi-asserted-by":"crossref","unstructured":"484 Randolph GW, Kamani D (2006) The importance of preoperative laryngoscopy in patients undergoing thyroidectomy: voice, vocal cord function, and the preoperative detection of invasive thyroid malignancy. Surgery 139: 357\u2013362.","DOI":"10.1016\/j.surg.2005.08.009"},{"key":"484","doi-asserted-by":"crossref","unstructured":"485 Lang BH CK, Tsang RK, Wong KP, Wong BY (2014) Evaluating the incidence, clinical significance and predictors for vocal cord palsy and incidental laryngopharyngeal conditions before elective thyroidectomy: is there a case for routine laryngoscopic examination? World J Surg 38: 385\u2013391.","DOI":"10.1007\/s00268-013-2259-3"},{"key":"485","doi-asserted-by":"crossref","unstructured":"486 Chandrasekhar SS, Randolph GW, Seidman MD, Rosenfeld RM, Angelos P, et al. (2013) Clinical practice guideline: improving voice outcomes after thyroid surgery. Otolaryngol Head Neck Surg 148: S1\u2013S37.","DOI":"10.1177\/0194599813487301"},{"key":"486","doi-asserted-by":"crossref","unstructured":"487 Tedla M, Chakrabarti S, Suchankova M, Weickert MO (2016) Voice outcomes after thyroidectomy without superior and recurrent laryngeal nerve injury: VoiSS questionnaire and GRBAS tool assessment. Eur Arch Otorhinolaryngol 273: 4543\u20134547.","DOI":"10.1007\/s00405-016-4163-6"},{"key":"487","doi-asserted-by":"crossref","unstructured":"488 Bergenfelz A, Jansson S, Kristoffersson A, Martensson H, Reihner E, et al. (2008) Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch Surg 393: 667\u2013673.","DOI":"10.1007\/s00423-008-0366-7"},{"key":"488","doi-asserted-by":"crossref","unstructured":"489 Jeannon JP, Orabi AA, Bruch GA, Abdalsalam HA, Simo R (2009) Diagnosis of recurrent laryngeal nerve palsy after thyroidectomy: a systematic review. Int J Clin Pract 63: 624\u2013629.","DOI":"10.1111\/j.1742-1241.2008.01875.x"},{"key":"489","doi-asserted-by":"crossref","unstructured":"490 Francis DO, Pearce EC, Ni S, Garrett CG, Penson DF (2014) Epidemiology of vocal fold paralyses after total thyroidectomy for well-differentiated thyroid cancer in a Medicare population. Otolaryngol Head Neck Surg 150: 548\u2013557.","DOI":"10.1177\/0194599814521381"},{"key":"490","doi-asserted-by":"publisher","unstructured":"491 Steurer M, Passler C, Denk DM, Schneider B, Niederle B, et al. (2002) Advantages of recurrent laryngeal nerve identification in thyroidectomy and parathyroidectomy and the importance of preoperative and postoperative laryngoscopic examination in more than 1,000 nerves at risk. Laryngoscope 112: 124\u2013133.","DOI":"10.1097\/00005537-200201000-00022"},{"key":"491","doi-asserted-by":"crossref","unstructured":"492 Paek SH, Lee YM, Min SY, Kim SW, Chung KW, et al. (2013) Risk factors of hypoparathyroidism following total thyroidectomy for thyroid cancer. World J Surg 37: 94\u2013101.","DOI":"10.1007\/s00268-012-1809-4"},{"key":"492","doi-asserted-by":"crossref","unstructured":"493 Qiu Y, Fei Y, Xing Z, Zhu J, Luo Y, et al. (2022) Does the number of autotransplanted parathyroid glands affect postoperative hypoparathyroidism and serum parathyroid hormone levels? Asian J Surg 45: 117\u2013124.","DOI":"10.1016\/j.asjsur.2021.03.031"},{"key":"493","doi-asserted-by":"crossref","unstructured":"494 Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP (2014) Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg 101: 307\u2013320.","DOI":"10.1002\/bjs.9384"},{"key":"494","doi-asserted-by":"crossref","unstructured":"495 Qiu Y, Xing Z, Qian Y, Fei Y, Luo Y, et al. (2021) Selective parathyroid autotransplantation during total thyroidectomy for PTC: a cohort study. Front Surg 8: 683041.","DOI":"10.3389\/fsurg.2021.683041"},{"key":"495","doi-asserted-by":"publisher","unstructured":"496 Kihara M, Miyauchi A (2014) Recovery of parathyroid function after total thyroidectomy. Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery 31: 5\u20138 (In Japanese).","DOI":"10.11226\/jaesjsts.31.1_5"},{"key":"496","doi-asserted-by":"crossref","unstructured":"497 Ito Y, Kihara M, Kobayashi K, Miya A, Miyauchi A (2014) Permanent hypoparathyroidism after completion total thyroidectomy as a second surgery: How do we avoid it? Endocr J 61: 403\u2013408.","DOI":"10.1507\/endocrj.EJ13-0503"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/5\/72_EJ24-0644\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T23:34:59Z","timestamp":1746833699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/5\/72_EJ24-0644\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":496,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0644","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0644"}}